index,title,abstract,Master Ref#,PubMed ID,Journal,Primary Author,Publication Year,Volume / Issue,Pages,Priority Journal,PubMed ID:,Full Reference:,"Study Outcome ($/QALY, $/DALY, Both):",Study Country:,Disease Classification:,Intervention Type(s):,Intervention Phrase vs. Comparator Phrase:,Target Characteristics:,Max Target Age:,Min Target Age:,Target Genders:,Review:,Time Horizon:,Discounting Rate (Costs):,Discounting Rate (QALYs):,Incremental Cost-Effectiveness Ratio (Original currency and year):,Currency Country:,Currency Year:,Incremental Cost-Effectiveness Ratio (Converted to current $USD):
29401,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Mauritania,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,171,United States,2012,192.76
29402,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Yemen,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,172,United States,2012,193.89
29403,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Zimbabwe,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,178,United States,2012,200.65
29404,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Pakistan,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,182,United States,2012,205.16
29405,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Ghana,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,188,United States,2012,211.92
29406,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Madagascar,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,195,United States,2012,219.81
29407,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Eritrea,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,219,United States,2012,246.87
29408,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Botswana,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,253,United States,2012,285.2
29409,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Haiti,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,257,United States,2012,289.7
29410,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Swaziland,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,274,United States,2012,308.87
29411,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Guatemala,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,316,United States,2012,356.21
29412,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,South Africa,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,321,United States,2012,361.85
29413,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Gabon,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,331,United States,2012,373.12
29414,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,India,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,333,United States,2012,375.38
29415,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Myanmar,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,337,United States,2012,379.88
29416,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Papua New Guinea,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,353,United States,2012,397.92
29417,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Iraq,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,466,United States,2012,525.3
29418,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Namibia,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,507,United States,2012,571.52
29419,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Cambodia,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,574,United States,2012,647.04
29420,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Nepal,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,729,United States,2012,821.77
29421,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Morocco,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,782,United States,2012,881.51
29422,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Bangladesh,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,1168,United States,2012,1316.63
29423,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Algeria,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,1253,United States,2012,1412.45
29424,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Uzbekistan,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,1406,United States,2012,1584.92
29425,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Ukraine,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,2036,United States,2012,2295.09
29426,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Thailand,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,2061,United States,2012,2323.27
29427,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Indonesia,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,2244,United States,2012,2529.56
29428,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Bolivia,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,2299,United States,2012,2591.56
29429,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Venezuela,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,2327,United States,2012,2623.12
29430,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Colombia,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,3098,United States,2012,3492.24
29431,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Peru,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,3126,United States,2012,3523.8
29432,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Brazil,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,3403,United States,2012,3836.05
29433,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Philippines,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,3597,United States,2012,4054.74
29434,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Russia,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,3907,United States,2012,4404.19
29435,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Argentina,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,5642,United States,2012,6359.97
29436,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Malaysia,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,5933,United States,2012,6688
29437,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Turkey,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,9501,United States,2012,10710.05
29438,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,Mexico,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,13989,United States,2012,15769.17
29439,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,"OBJECTIVE: This study estimated the health impact, cost and cost-effectiveness of an integrated prevention campaign (IPC) focused on diarrhoea, malaria and HIV in 70 countries ranked by per capita disability-adjusted life-year (DALY) burden for the three diseases. METHODS: We constructed a deterministic cost-effectiveness model portraying an IPC combining counselling and testing, cotrimoxazole prophylaxis, referral to treatment and condom distribution for HIV prevention; bed nets for malaria prevention; and provision of household water filters for diarrhoea prevention. We developed a mix of empirical and modelled cost and health impact estimates applied to all 70 countries. One-way, multiway and scenario sensitivity analyses were conducted to document the strength of our findings. We used a healthcare payer's perspective, discounted costs and DALYs at 3% per year and denominated cost in 2012 US dollars. PRIMARY AND SECONDARY OUTCOMES: The primary outcome was cost-effectiveness expressed as net cost per DALY averted. Other outcomes included cost of the IPC; net IPC costs adjusted for averted and additional medical costs and DALYs averted. RESULTS: Implementation of the IPC in the 10 most cost-effective countries at 15% population coverage would cost US$583 million over 3 years (adjusted costs of US$398 million), averting 8.0 million DALYs. Extending IPC programmes to all 70 of the identified high-burden countries at 15% coverage would cost an adjusted US$51.3 billion and avert 78.7 million DALYs. Incremental cost-effectiveness ranged from US$49 per DALY averted for the 10 countries with the most favourable cost-effectiveness to US$119, US$181, US$335, US$1692 and US$8340 per DALY averted as each successive group of 10 countries is added ordered by decreasing cost-effectiveness. CONCLUSIONS: IPC appears cost-effective in many settings, and has the potential to substantially reduce the burden of disease in resource-poor countries. This study increases confidence that IPC can be an important new approach for enhancing global health.",2014-99-16318,24969782,BMJ Open,Elliot Marseille,2014,4 / 6,e003987,No,24969782,"Elliot Marseille; Aliya Jiwani; Abhishek Raut; Stephane Verguet; Judd Walson; James G Kahn; Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries, BMJ Open , ; 4(6):2044-6055; e003987",DALY,China,Not Stated,"Environmental, Health Education or Behavior, Pharmaceutical, Screening","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,15886,United States,2012,17907.57
29440,Reaching the london declaration on neglected tropical diseases goals for onchocerciasis: an economic evaluation of increasing the frequency of ivermectin treatment in Africa,"BACKGROUND: Recently, there has been a shift in onchocerciasis control policy, changing from prevention of morbidity toward elimination of infection. Switching from annual to biannual ivermectin distribution may accelerate progress toward the elimination goals. However, the settings where this strategy would be cost effective in Africa have not been described. METHODS: An onchocerciasis transmission framework (EpiOncho) was coupled to a disease model in order to explore the impact on disability-adjusted life years averted, program cost, and program duration of biannual ivermectin treatment in different epidemiological and programmatic scenarios in African savannah. RESULTS: While biannual treatment yields only small additional health gains, its benefit is pronounced in the context of the elimination goals, shortening the time frames for and increasing the feasibility of reaching the proposed operational thresholds for stopping treatment. In settings with high precontrol endemicity (and/or poor coverage and compliance), it may not be possible to reach such thresholds even within 50 years of annual ivermectin, requiring adoption of biannual treatment. Our projections highlight the crucial role played by coverage and compliance in achieving the elimination goals. CONCLUSIONS: Biannual ivermectin treatment improves the chances of reaching the 2020/2025 elimination goals, potentially generating programmatic cost savings in settings with high precontrol endemicity. However, its benefit and cost are highly sensitive to levels of systematic noncompliance and, in many settings, it will lead to an increase in costs. Furthermore, it may not always be feasible to implement biannual treatment, particularly in hard-to-reach populations. This highlights the continued need for a macrofilaricide.",2014-99-16367,24944228,Clin Infect Dis,Hugo C Turner,2014,59 / 7,923-32,No,24944228,"Hugo C Turner; Martin Walker; Thomas S Churcher; Mike Y Osei-Atweneboana; Nana-Kwadwo Biritwum; Adrian Hopkins; Roger K Prichard; Maria-Gloria Basanez; Reaching the london declaration on neglected tropical diseases goals for onchocerciasis: an economic evaluation of increasing the frequency of ivermectin treatment in Africa, Clin Infect Dis, ; 59(7):1537-6591; 923-32",DALY,"Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cabo Verde, Cameroon, Central African Republic, Chad, Congo Democratic Republic, Comoros, Congo, Cte d'Ivoire, Djibouti, Egypt, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, Mauritius, Morocco, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, Sudan, Swaziland, Tanzania, Togo, Tunisia, Uganda, Zambia, Zimbabwe",Not Stated,Pharmaceutical,Community-directed annual mass drug administration (MDA) with ivermectin (Mectizan) to prevent onchocerciasis vs. None,Hyperendemic (60% microfilarial prevalence),Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,6,United States,2012,6.76
29441,Reaching the london declaration on neglected tropical diseases goals for onchocerciasis: an economic evaluation of increasing the frequency of ivermectin treatment in Africa,"BACKGROUND: Recently, there has been a shift in onchocerciasis control policy, changing from prevention of morbidity toward elimination of infection. Switching from annual to biannual ivermectin distribution may accelerate progress toward the elimination goals. However, the settings where this strategy would be cost effective in Africa have not been described. METHODS: An onchocerciasis transmission framework (EpiOncho) was coupled to a disease model in order to explore the impact on disability-adjusted life years averted, program cost, and program duration of biannual ivermectin treatment in different epidemiological and programmatic scenarios in African savannah. RESULTS: While biannual treatment yields only small additional health gains, its benefit is pronounced in the context of the elimination goals, shortening the time frames for and increasing the feasibility of reaching the proposed operational thresholds for stopping treatment. In settings with high precontrol endemicity (and/or poor coverage and compliance), it may not be possible to reach such thresholds even within 50 years of annual ivermectin, requiring adoption of biannual treatment. Our projections highlight the crucial role played by coverage and compliance in achieving the elimination goals. CONCLUSIONS: Biannual ivermectin treatment improves the chances of reaching the 2020/2025 elimination goals, potentially generating programmatic cost savings in settings with high precontrol endemicity. However, its benefit and cost are highly sensitive to levels of systematic noncompliance and, in many settings, it will lead to an increase in costs. Furthermore, it may not always be feasible to implement biannual treatment, particularly in hard-to-reach populations. This highlights the continued need for a macrofilaricide.",2014-99-16367,24944228,Clin Infect Dis,Hugo C Turner,2014,59 / 7,923-32,No,24944228,"Hugo C Turner; Martin Walker; Thomas S Churcher; Mike Y Osei-Atweneboana; Nana-Kwadwo Biritwum; Adrian Hopkins; Roger K Prichard; Maria-Gloria Basanez; Reaching the london declaration on neglected tropical diseases goals for onchocerciasis: an economic evaluation of increasing the frequency of ivermectin treatment in Africa, Clin Infect Dis, ; 59(7):1537-6591; 923-32",DALY,"Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cabo Verde, Cameroon, Central African Republic, Chad, Congo Democratic Republic, Comoros, Congo, Cte d'Ivoire, Djibouti, Egypt, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, Mauritius, Morocco, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, Sudan, Swaziland, Tanzania, Togo, Tunisia, Uganda, Zambia, Zimbabwe",Not Stated,Pharmaceutical,Community-directed biannual mass drug administration (MDA) with ivermectin (Mectizan) to prevent onchocerciasis vs. community-directed annual mass drug administration (MDA) with ivermectin,Hyperendemic (60% microfilarial prevalence),Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,36,United States,2012,40.58
29442,The cost-effectiveness of orthopaedic clinical officers in Malawi,"BACKGROUND: In Malawi the orthopaedic clinical officer (OCO) training programme trains non-physician clinicians in musculoskeletal care. We studied the cost-effectiveness of this program. METHODS: Hospital logbooks were reviewed for data pertaining to activity in seven district hospitals over a 6-month period. The total costs were divided by the total effectiveness, calculated as disability adjusted life years (DALYs) averted. RESULTS: The total cost-effectiveness of providing orthopaedic care through the OCO training programme was US$92.06 per DALY averted. The mean per hospital was US$138.75 (95% CI: US$69.58-207.91) per DALY averted which is very cost-effective when compared with other health interventions. Of the 837 patients treated 63% were aged <15 years and 36% were in the 'economically active' demographic of ages 15-74 years. CONCLUSION: Training of clinical officers in orthopaedic surgery is very cost-effective and allows transfer of skills into rural areas. The demographics suggest that failure to provide such care would have a negative economic impact.",2014-99-16600,24821618,Trop Doct,Caris E Grimes,2014,44 / 3,128-134,No,24821618,"Caris E Grimes; Nyengo C Mkandawire; Michael L Billingsley; Christopher Ngulube; James C Cobey; The cost-effectiveness of orthopaedic clinical officers in Malawi, Trop Doct, ; 44(3):1758-1133; 128-134",DALY,Malawi,Not Stated,"Care Delivery, Health Education or Behavior, Medical Procedure",Orthopedic treatment at rural hospitals by orthopedic clinical officers (OCO) who are non-physician clinicians vs. Standard/Usual Care,Not Stated,Not Stated,6 Years,"Female, Male",Full,,Not Stated,Not Stated,92.06,United States,2012,103.78
29443,Cost-effectiveness of a tuberculosis active case finding program targeting household and neighborhood contacts in Cambodia,"In many high-risk populations, access to tuberculosis (TB) diagnosis and treatment is limited and pockets of high prevalence persist. We estimated the cost-effectiveness of an extensive active case finding program in areas of Cambodia where TB notifications and household poverty rates are highest and access to care is restricted. Thirty operational health districts with high TB incidence and household poverty were randomized into intervention and control groups. In intervention operational health districts, all household and symptomatic neighborhood contacts of registered TB patients of the past two years were encouraged to attend screening at mobile centers. In control districts, routine passive case finding activities continued. The program screened more than 35,000 household and neighborhood contacts and identified 810 bacteriologically confirmed cases. The cost-effectiveness analysis estimated that in these cases the reduction in mortality from 14% to 2% would result in a cost per daily adjusted life year averted of $330, suggesting that active case finding was highly cost-effective.",2014-99-16895,24615134,Am J Trop Med Hyg,Rajendra P Yadav,2014,90 / 5,866-72,No,24615134,"Rajendra P Yadav; Nobuyuki Nishikiori; Peou Satha; Mao T Eang; Yoel Lubell; Cost-effectiveness of a tuberculosis active case finding program targeting household and neighborhood contacts in Cambodia, Am J Trop Med Hyg, ; 90(5):0002-9637; 866-72",DALY,Cambodia,Not Stated,"Diagnostic, Screening",Active case finding (ACF) to identify and treat TB patients (household visits from community volunteers and health workers to motivate patients and household contacts to visit ACF sites) vs. Standard/Usual Care- Passive case finding using microscopy,Household and symptomatic neighborhood contacts of known TB cases,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,330,United States,2012,371.99
29444,Economic efficiency of sanitation interventions in Southeast Asia,"Economic evidence on sanitation supports decisions on resource allocation and selection of efficient and affordable sanitation interventions. This study presents the economic efficiency (costs versus benefits) of sanitation interventions to better manage human excreta, from 47 field sites, covering six countries of Southeast Asia (Cambodia, China, Indonesia, Lao PDR, the Philippines and Vietnam). Costs were estimated in each location, while benefits (improved health, avoided water pollution, reduced sanitation access time, resource recovery) were estimated using evidence from published studies and field sites. The economic return per currency unit invested, known as the benefit-cost ratio (BCR), and the cost per disability-adjusted life-year (DALY) averted were estimated. Across 25 rural field sites, pit latrines had a BCR of at least 5 in all countries, except Cambodia where the BCR was 2. In 22 urban field sites, septic tanks with wastewater management had a BCR of at least 2. Costs per DALY averted were found to be 'cost-effective' for most sanitation interventions in all countries. Economic performance declined significantly when considering non-use of facilities by households or unused infrastructural capacity. However, the economic net returns were positive under all pessimistic scenarios examined in one-way sensitivity analysis. This study demonstrates that sanitation is a highly profitable social and economic investment in six Asian countries.",2014-01-03187,0,J. Wate Sanit. Hyg. Dev.,Guy Hutton,2014,4 / 1,23-36,No,Not Stated,"Guy Hutton; Andrew Kingston; Karen Davies; Joanna Collerton; Louise Robinson; Rachel Duncan; Thomas B. L. Kirkwood; Carol Jagger; Chad Hochberg; Eugenio Maul; Emilie S. Chan; Suzanne Van Landingham; Luigi Ferrucci; David S. Friedman; Pradeep Y. Ramulu; Daniel F. Mackay; Rachael Wood; Albert King; David N. Clark; Sally-Ann Cooper; Gordon C. S. Smith; Jill P. Pell; U-Primo Rodriguez; Asep Winara; Nguyen Viet Anh; Kov Phyrum; Liang Chuan; Isabel Blackett; Almud Weitz; Glenio Cesar Nunes Ferrer; Rosemeri Maurici da Silva; Kelian Tenfen Ferrer; Jefferson Traebert; Ivo Vlaev; Ben Seymour; Nick Chater; Joel S. Winston; Wako Yoshida; Nicholas Wright; Mkael Symmonds; Ray Dolan; Economic efficiency of sanitation interventions in Southeast Asia, J. Wate Sanit. Hyg. Dev., ; 4(1):2043-9083; 23-36",DALY,Cambodia,Not Stated,Environmental,Wet pit latrines in rural areas vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,8.00,8.00,500,United States,2008,601.04
29445,Economic efficiency of sanitation interventions in Southeast Asia,"Economic evidence on sanitation supports decisions on resource allocation and selection of efficient and affordable sanitation interventions. This study presents the economic efficiency (costs versus benefits) of sanitation interventions to better manage human excreta, from 47 field sites, covering six countries of Southeast Asia (Cambodia, China, Indonesia, Lao PDR, the Philippines and Vietnam). Costs were estimated in each location, while benefits (improved health, avoided water pollution, reduced sanitation access time, resource recovery) were estimated using evidence from published studies and field sites. The economic return per currency unit invested, known as the benefit-cost ratio (BCR), and the cost per disability-adjusted life-year (DALY) averted were estimated. Across 25 rural field sites, pit latrines had a BCR of at least 5 in all countries, except Cambodia where the BCR was 2. In 22 urban field sites, septic tanks with wastewater management had a BCR of at least 2. Costs per DALY averted were found to be 'cost-effective' for most sanitation interventions in all countries. Economic performance declined significantly when considering non-use of facilities by households or unused infrastructural capacity. However, the economic net returns were positive under all pessimistic scenarios examined in one-way sensitivity analysis. This study demonstrates that sanitation is a highly profitable social and economic investment in six Asian countries.",2014-01-03187,0,J. Wate Sanit. Hyg. Dev.,Guy Hutton,2014,4 / 1,23-36,No,Not Stated,"Guy Hutton; Andrew Kingston; Karen Davies; Joanna Collerton; Louise Robinson; Rachel Duncan; Thomas B. L. Kirkwood; Carol Jagger; Chad Hochberg; Eugenio Maul; Emilie S. Chan; Suzanne Van Landingham; Luigi Ferrucci; David S. Friedman; Pradeep Y. Ramulu; Daniel F. Mackay; Rachael Wood; Albert King; David N. Clark; Sally-Ann Cooper; Gordon C. S. Smith; Jill P. Pell; U-Primo Rodriguez; Asep Winara; Nguyen Viet Anh; Kov Phyrum; Liang Chuan; Isabel Blackett; Almud Weitz; Glenio Cesar Nunes Ferrer; Rosemeri Maurici da Silva; Kelian Tenfen Ferrer; Jefferson Traebert; Ivo Vlaev; Ben Seymour; Nick Chater; Joel S. Winston; Wako Yoshida; Nicholas Wright; Mkael Symmonds; Ray Dolan; Economic efficiency of sanitation interventions in Southeast Asia, J. Wate Sanit. Hyg. Dev., ; 4(1):2043-9083; 23-36",DALY,Indonesia,Not Stated,Environmental,Wet pit latrines in rural areas vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,8.00,8.00,700,United States,2008,841.45
29446,Economic efficiency of sanitation interventions in Southeast Asia,"Economic evidence on sanitation supports decisions on resource allocation and selection of efficient and affordable sanitation interventions. This study presents the economic efficiency (costs versus benefits) of sanitation interventions to better manage human excreta, from 47 field sites, covering six countries of Southeast Asia (Cambodia, China, Indonesia, Lao PDR, the Philippines and Vietnam). Costs were estimated in each location, while benefits (improved health, avoided water pollution, reduced sanitation access time, resource recovery) were estimated using evidence from published studies and field sites. The economic return per currency unit invested, known as the benefit-cost ratio (BCR), and the cost per disability-adjusted life-year (DALY) averted were estimated. Across 25 rural field sites, pit latrines had a BCR of at least 5 in all countries, except Cambodia where the BCR was 2. In 22 urban field sites, septic tanks with wastewater management had a BCR of at least 2. Costs per DALY averted were found to be 'cost-effective' for most sanitation interventions in all countries. Economic performance declined significantly when considering non-use of facilities by households or unused infrastructural capacity. However, the economic net returns were positive under all pessimistic scenarios examined in one-way sensitivity analysis. This study demonstrates that sanitation is a highly profitable social and economic investment in six Asian countries.",2014-01-03187,0,J. Wate Sanit. Hyg. Dev.,Guy Hutton,2014,4 / 1,23-36,No,Not Stated,"Guy Hutton; Andrew Kingston; Karen Davies; Joanna Collerton; Louise Robinson; Rachel Duncan; Thomas B. L. Kirkwood; Carol Jagger; Chad Hochberg; Eugenio Maul; Emilie S. Chan; Suzanne Van Landingham; Luigi Ferrucci; David S. Friedman; Pradeep Y. Ramulu; Daniel F. Mackay; Rachael Wood; Albert King; David N. Clark; Sally-Ann Cooper; Gordon C. S. Smith; Jill P. Pell; U-Primo Rodriguez; Asep Winara; Nguyen Viet Anh; Kov Phyrum; Liang Chuan; Isabel Blackett; Almud Weitz; Glenio Cesar Nunes Ferrer; Rosemeri Maurici da Silva; Kelian Tenfen Ferrer; Jefferson Traebert; Ivo Vlaev; Ben Seymour; Nick Chater; Joel S. Winston; Wako Yoshida; Nicholas Wright; Mkael Symmonds; Ray Dolan; Economic efficiency of sanitation interventions in Southeast Asia, J. Wate Sanit. Hyg. Dev., ; 4(1):2043-9083; 23-36",DALY,Lao,Not Stated,Environmental,Wet pit latrines in rural areas vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,8.00,8.00,550,United States,2008,661.14
29447,Economic efficiency of sanitation interventions in Southeast Asia,"Economic evidence on sanitation supports decisions on resource allocation and selection of efficient and affordable sanitation interventions. This study presents the economic efficiency (costs versus benefits) of sanitation interventions to better manage human excreta, from 47 field sites, covering six countries of Southeast Asia (Cambodia, China, Indonesia, Lao PDR, the Philippines and Vietnam). Costs were estimated in each location, while benefits (improved health, avoided water pollution, reduced sanitation access time, resource recovery) were estimated using evidence from published studies and field sites. The economic return per currency unit invested, known as the benefit-cost ratio (BCR), and the cost per disability-adjusted life-year (DALY) averted were estimated. Across 25 rural field sites, pit latrines had a BCR of at least 5 in all countries, except Cambodia where the BCR was 2. In 22 urban field sites, septic tanks with wastewater management had a BCR of at least 2. Costs per DALY averted were found to be 'cost-effective' for most sanitation interventions in all countries. Economic performance declined significantly when considering non-use of facilities by households or unused infrastructural capacity. However, the economic net returns were positive under all pessimistic scenarios examined in one-way sensitivity analysis. This study demonstrates that sanitation is a highly profitable social and economic investment in six Asian countries.",2014-01-03187,0,J. Wate Sanit. Hyg. Dev.,Guy Hutton,2014,4 / 1,23-36,No,Not Stated,"Guy Hutton; Andrew Kingston; Karen Davies; Joanna Collerton; Louise Robinson; Rachel Duncan; Thomas B. L. Kirkwood; Carol Jagger; Chad Hochberg; Eugenio Maul; Emilie S. Chan; Suzanne Van Landingham; Luigi Ferrucci; David S. Friedman; Pradeep Y. Ramulu; Daniel F. Mackay; Rachael Wood; Albert King; David N. Clark; Sally-Ann Cooper; Gordon C. S. Smith; Jill P. Pell; U-Primo Rodriguez; Asep Winara; Nguyen Viet Anh; Kov Phyrum; Liang Chuan; Isabel Blackett; Almud Weitz; Glenio Cesar Nunes Ferrer; Rosemeri Maurici da Silva; Kelian Tenfen Ferrer; Jefferson Traebert; Ivo Vlaev; Ben Seymour; Nick Chater; Joel S. Winston; Wako Yoshida; Nicholas Wright; Mkael Symmonds; Ray Dolan; Economic efficiency of sanitation interventions in Southeast Asia, J. Wate Sanit. Hyg. Dev., ; 4(1):2043-9083; 23-36",DALY,Philippines,Not Stated,Environmental,Wet pit latrines in rural areas vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,8.00,8.00,2400,United States,2008,2884.99
29448,Economic efficiency of sanitation interventions in Southeast Asia,"Economic evidence on sanitation supports decisions on resource allocation and selection of efficient and affordable sanitation interventions. This study presents the economic efficiency (costs versus benefits) of sanitation interventions to better manage human excreta, from 47 field sites, covering six countries of Southeast Asia (Cambodia, China, Indonesia, Lao PDR, the Philippines and Vietnam). Costs were estimated in each location, while benefits (improved health, avoided water pollution, reduced sanitation access time, resource recovery) were estimated using evidence from published studies and field sites. The economic return per currency unit invested, known as the benefit-cost ratio (BCR), and the cost per disability-adjusted life-year (DALY) averted were estimated. Across 25 rural field sites, pit latrines had a BCR of at least 5 in all countries, except Cambodia where the BCR was 2. In 22 urban field sites, septic tanks with wastewater management had a BCR of at least 2. Costs per DALY averted were found to be 'cost-effective' for most sanitation interventions in all countries. Economic performance declined significantly when considering non-use of facilities by households or unused infrastructural capacity. However, the economic net returns were positive under all pessimistic scenarios examined in one-way sensitivity analysis. This study demonstrates that sanitation is a highly profitable social and economic investment in six Asian countries.",2014-01-03187,0,J. Wate Sanit. Hyg. Dev.,Guy Hutton,2014,4 / 1,23-36,No,Not Stated,"Guy Hutton; Andrew Kingston; Karen Davies; Joanna Collerton; Louise Robinson; Rachel Duncan; Thomas B. L. Kirkwood; Carol Jagger; Chad Hochberg; Eugenio Maul; Emilie S. Chan; Suzanne Van Landingham; Luigi Ferrucci; David S. Friedman; Pradeep Y. Ramulu; Daniel F. Mackay; Rachael Wood; Albert King; David N. Clark; Sally-Ann Cooper; Gordon C. S. Smith; Jill P. Pell; U-Primo Rodriguez; Asep Winara; Nguyen Viet Anh; Kov Phyrum; Liang Chuan; Isabel Blackett; Almud Weitz; Glenio Cesar Nunes Ferrer; Rosemeri Maurici da Silva; Kelian Tenfen Ferrer; Jefferson Traebert; Ivo Vlaev; Ben Seymour; Nick Chater; Joel S. Winston; Wako Yoshida; Nicholas Wright; Mkael Symmonds; Ray Dolan; Economic efficiency of sanitation interventions in Southeast Asia, J. Wate Sanit. Hyg. Dev., ; 4(1):2043-9083; 23-36",DALY,Viet Nam,Not Stated,Environmental,Wet pit latrines in rural areas vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,8.00,8.00,1000,United States,2008,1202.08
29449,Economic efficiency of sanitation interventions in Southeast Asia,"Economic evidence on sanitation supports decisions on resource allocation and selection of efficient and affordable sanitation interventions. This study presents the economic efficiency (costs versus benefits) of sanitation interventions to better manage human excreta, from 47 field sites, covering six countries of Southeast Asia (Cambodia, China, Indonesia, Lao PDR, the Philippines and Vietnam). Costs were estimated in each location, while benefits (improved health, avoided water pollution, reduced sanitation access time, resource recovery) were estimated using evidence from published studies and field sites. The economic return per currency unit invested, known as the benefit-cost ratio (BCR), and the cost per disability-adjusted life-year (DALY) averted were estimated. Across 25 rural field sites, pit latrines had a BCR of at least 5 in all countries, except Cambodia where the BCR was 2. In 22 urban field sites, septic tanks with wastewater management had a BCR of at least 2. Costs per DALY averted were found to be 'cost-effective' for most sanitation interventions in all countries. Economic performance declined significantly when considering non-use of facilities by households or unused infrastructural capacity. However, the economic net returns were positive under all pessimistic scenarios examined in one-way sensitivity analysis. This study demonstrates that sanitation is a highly profitable social and economic investment in six Asian countries.",2014-01-03187,0,J. Wate Sanit. Hyg. Dev.,Guy Hutton,2014,4 / 1,23-36,No,Not Stated,"Guy Hutton; Andrew Kingston; Karen Davies; Joanna Collerton; Louise Robinson; Rachel Duncan; Thomas B. L. Kirkwood; Carol Jagger; Chad Hochberg; Eugenio Maul; Emilie S. Chan; Suzanne Van Landingham; Luigi Ferrucci; David S. Friedman; Pradeep Y. Ramulu; Daniel F. Mackay; Rachael Wood; Albert King; David N. Clark; Sally-Ann Cooper; Gordon C. S. Smith; Jill P. Pell; U-Primo Rodriguez; Asep Winara; Nguyen Viet Anh; Kov Phyrum; Liang Chuan; Isabel Blackett; Almud Weitz; Glenio Cesar Nunes Ferrer; Rosemeri Maurici da Silva; Kelian Tenfen Ferrer; Jefferson Traebert; Ivo Vlaev; Ben Seymour; Nick Chater; Joel S. Winston; Wako Yoshida; Nicholas Wright; Mkael Symmonds; Ray Dolan; Economic efficiency of sanitation interventions in Southeast Asia, J. Wate Sanit. Hyg. Dev., ; 4(1):2043-9083; 23-36",DALY,China,Not Stated,Environmental,Wet pit latrines in rural areas vs. None,Yunnan,Not Stated,19 Years,"Female, Male",Full,,8.00,8.00,1000,United States,2008,1202.08
29450,Dihydroartemisinin-piperaquine vs. artemether-lumefantrine for first-line treatment of uncomplicated malaria in African children: A cost-effectiveness analysis,"Background: Recent multi-centre trials showed that dihydroartemisinin- piperaquine (DP) was as efficacious and safe as artemether-lumefantrine (AL) for treatment of young children with uncomplicated P. falciparum malaria across diverse transmission settings in Africa. Longitudinal follow-up of patients in these trials supported previous findings that DP had a longer post-treatment prophylactic effect than AL, reducing the risk of reinfection and conferring additional health benefits to patients, particularly in areas with moderate to high malaria transmission. Methods: We developed a Markov model to assess the cost-effectiveness of DP versus AL for first-line treatment of uncomplicated malaria in young children from the provider perspective, taking into consideration the post-treatment prophylactic effects of the drugs as reported by a recent multi-centre trial in Africa and using the maximum manufacturer drug prices for artemisinin-based combination therapies set by the Global Fund in 2013. We estimated the price per course of treatment threshold above which DP would cease to be a cost-saving alternative to AL as a first-line antimalarial drug. Results: First-line treatment with DP compared to AL averted 0.03 DALYs (95% CI: 0.006-0.07) and 0.001 deaths (95% CI: 0.00-0.002) and saved $0.96 (95% CI: 0.33-2.46) per child over one year. The results of the threshold analysis showed that DP remained cost-saving over AL for any DP cost below $1.23 per course of treatment. Conclusions: DP is superior to AL from both the clinical and economic perspectives for treatment of uncomplicated P. falciparum malaria in young children. A paediatric dispersible formulation of DP is under development and should facilitate a targeted deployment of this antimalarial drug. The use of DP as first-line antimalarial drug in paediatric malaria patients in moderate to high transmission areas of Africa merits serious consideration by health policymakers.  2014 Pfeil et al.",2014-01-04289,24748395,PLoS One,,2014,9 /,,No,24748395,"Michele Baumann; Etienne Le Bihan; Kenora Chau; Nearkasen Chau; Linda Cobiac; Theo Vos; Lennert Veerman; Gita D. Mishra; Stephanie Black; Mai Stafford; Rachel Cooper; Diana Kuh; Dihydroartemisinin-piperaquine vs. artemether-lumefantrine for first-line treatment of uncomplicated malaria in African children: A cost-effectiveness analysis, PLoS One , 2014; 9():1932-6203",DALY,Not Stated,Not Stated,Pharmaceutical,Not Stated,Not Stated,5 Years,Not Stated,"Female, Male",Full,,Not Stated,3.00,-32.33,United States,2013,-35.92
29459,Cost-effectiveness of a comprehensive programme for drug-resistant tuberculosis in China,"OBJECTIVE: To investigate the cost-effectiveness of a comprehensive programme for drug-resistant tuberculosis launched in four sites in China in 2011. METHODS: In 2011-2012, we reviewed the records of 172 patients with drug-resistant tuberculosis who enrolled in the comprehensive programme and we collected relevant administrative data from hospitals and China's public health agency. For comparison, we examined a cohort of 81 patients who were treated for drug-resistant tuberculosis in 2006-2009. We performed a cost-effectiveness analysis, from a societal perspective, that included probabilistic uncertainty. We measured early treatment outcomes based on three-month culture results and modelled longer-term outcomes to facilitate estimation of the comprehensive programme's cost per disability-adjusted life-year (DALY) averted. FINDINGS: The comprehensive programme cost 8837 United States dollars (US$) per patient treated. Low enrolment rates meant that some fixed costs were higher, per patient, than expected. Although the comprehensive programme appeared 30 times more costly than the previous one, it resulted in greater health benefits. The comprehensive programme, which cost US$ 639 (95% credible interval: 112 to 1322) per DALY averted, satisfied the World Health Organization's criterion for a very cost-effective intervention. CONCLUSION: The comprehensive programme, which included rapid screening, standardized care and financial protection, improved individual outcomes for MDR tuberculosis in a cost-effective manner. To support post-2015 global heath targets, the comprehensive programme should be expanded to non-residents and other areas of China.",2015-99-20735,26549905,Bull World Health Organ,Christopher Fitzpatrick,2015,93 / 11,775-84,No,26549905,"Christopher Fitzpatrick; Zhang Hui; Wang Lixia; Li Renzhong; Ruan Yunzhou; Chen Mingting; Zhao Yanlin; Zhao Jin; Su Wei; Xu Caihong; Chen Cheng; Timothy Alston; Qu Yan; Lv Chengfei; Fu Yunting; Huan Shitong; Sun Qiang; Fabio Scano; Daniel P Chin; Katherine Floyd; Cost-effectiveness of a comprehensive programme for drug-resistant tuberculosis in China, Bull World Health Organ, 2015 Nov 1; 93(11):0042-9686; 775-84",DALY,China,Not Stated,"Pharmaceutical, Screening","Comprehensive programme included screening of all patients with sputum-smear-positive pulmonary tuberculosis, rapid diagnosis, standardized care and financial protection against catastrophic health expenditure vs. Standard/Usual Care- conventional drug-susceptibility testing recommended for all newly-diagnosed patients and for all previously-treated patients","Patients with drug-resistant tuberculosis, primary and secondary patients",Not Stated,12 Years,"Female, Male",Full,,3.00,Not Stated,250.17,China,2011,44.55
29460,Cost-effectiveness of a comprehensive programme for drug-resistant tuberculosis in China,"OBJECTIVE: To investigate the cost-effectiveness of a comprehensive programme for drug-resistant tuberculosis launched in four sites in China in 2011. METHODS: In 2011-2012, we reviewed the records of 172 patients with drug-resistant tuberculosis who enrolled in the comprehensive programme and we collected relevant administrative data from hospitals and China's public health agency. For comparison, we examined a cohort of 81 patients who were treated for drug-resistant tuberculosis in 2006-2009. We performed a cost-effectiveness analysis, from a societal perspective, that included probabilistic uncertainty. We measured early treatment outcomes based on three-month culture results and modelled longer-term outcomes to facilitate estimation of the comprehensive programme's cost per disability-adjusted life-year (DALY) averted. FINDINGS: The comprehensive programme cost 8837 United States dollars (US$) per patient treated. Low enrolment rates meant that some fixed costs were higher, per patient, than expected. Although the comprehensive programme appeared 30 times more costly than the previous one, it resulted in greater health benefits. The comprehensive programme, which cost US$ 639 (95% credible interval: 112 to 1322) per DALY averted, satisfied the World Health Organization's criterion for a very cost-effective intervention. CONCLUSION: The comprehensive programme, which included rapid screening, standardized care and financial protection, improved individual outcomes for MDR tuberculosis in a cost-effective manner. To support post-2015 global heath targets, the comprehensive programme should be expanded to non-residents and other areas of China.",2015-99-20735,26549905,Bull World Health Organ,Christopher Fitzpatrick,2015,93 / 11,775-84,No,26549905,"Christopher Fitzpatrick; Zhang Hui; Wang Lixia; Li Renzhong; Ruan Yunzhou; Chen Mingting; Zhao Yanlin; Zhao Jin; Su Wei; Xu Caihong; Chen Cheng; Timothy Alston; Qu Yan; Lv Chengfei; Fu Yunting; Huan Shitong; Sun Qiang; Fabio Scano; Daniel P Chin; Katherine Floyd; Cost-effectiveness of a comprehensive programme for drug-resistant tuberculosis in China, Bull World Health Organ, 2015 Nov 1; 93(11):0042-9686; 775-84",DALY,China,Not Stated,"Pharmaceutical, Screening","Comprehensive programme included screening of all patients with sputum-smear-positive pulmonary tuberculosis, rapid diagnosis, standardized care and financial protection against catastrophic health expenditure vs. None","Patients with drug-resistant tuberculosis, primary and secondary patients",Not Stated,12 Years,"Female, Male",Full,,3.00,Not Stated,355.23,China,2011,63.25
29461,"Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models","BACKGROUND: The phase 3 trial of the RTS,S/AS01 malaria vaccine candidate showed modest efficacy of the vaccine against Plasmodium falciparum malaria, but was not powered to assess mortality endpoints. Impact projections and cost-effectiveness estimates for longer timeframes than the trial follow-up and across a range of settings are needed to inform policy recommendations. We aimed to assess the public health impact and cost-effectiveness of routine use of the RTS,S/AS01 vaccine in African settings. METHODS: We compared four malaria transmission models and their predictions to assess vaccine cost-effectiveness and impact. We used trial data for follow-up of 32 months or longer to parameterise vaccine protection in the group aged 5-17 months. Estimates of cases, deaths, and disability-adjusted life-years (DALYs) averted were calculated over a 15 year time horizon for a range of levels of Plasmodium falciparum parasite prevalence in 2-10 year olds (PfPR2-10; range 3-65%). We considered two vaccine schedules: three doses at ages 6, 7.5, and 9 months (three-dose schedule, 90% coverage) and including a fourth dose at age 27 months (four-dose schedule, 72% coverage). We estimated cost-effectiveness in the presence of existing malaria interventions for vaccine prices of US$2-10 per dose. FINDINGS: In regions with a PfPR2-10 of 10-65%, RTS,S/AS01 is predicted to avert a median of 93,940 (range 20,490-126,540) clinical cases and 394 (127-708) deaths for the three-dose schedule, or 116,480 (31,450-160,410) clinical cases and 484 (189-859) deaths for the four-dose schedule, per 100,000 fully vaccinated children. A positive impact is also predicted at a PfPR2-10 of 5-10%, but there is little impact at a prevalence of lower than 3%. At $5 per dose and a PfPR2-10 of 10-65%, we estimated a median incremental cost-effectiveness ratio compared with current interventions of $30 (range 18-211) per clinical case averted and $80 (44-279) per DALY averted for the three-dose schedule, and of $25 (16-222) and $87 (48-244), respectively, for the four-dose schedule. Higher ICERs were estimated at low PfPR2-10 levels. INTERPRETATION: We predict a significant public health impact and high cost-effectiveness of the RTS,S/AS01 vaccine across a wide range of settings. Decisions about implementation will need to consider levels of malaria burden, the cost-effectiveness and coverage of other malaria interventions, health priorities, financing, and the capacity of the health system to deliver the vaccine. FUNDING: PATH Malaria Vaccine Initiative; Bill & Melinda Gates Foundation; Global Good Fund; Medical Research Council; UK Department for International Development; GAVI, the Vaccine Alliance; WHO.",2016-XX-20736,26549466,Lancet,Melissa A Penny,2016,387 / 10016,367-75,No,26549466,"Melissa A Penny; Robert Verity; Caitlin A Bever; Christophe Sauboin; Katya Galactionova; Stefan Flasche; Michael T White; Edward A Wenger; Nicolas Van de Velde; Peter Pemberton-Ross; Jamie T Griffin; Thomas A Smith; Philip A Eckhoff; Farzana Muhib; Mark Jit; Azra C Ghani; Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models, Lancet, 2016 Jan 23; 387(10016):0140-6736; 367-75",DALY,Ethiopia,Not Stated,Immunization,"RTS,S/AS01 malaria vaccine, 3 doses (cost $2 per dose) vs. None",Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,Not Stated,35,United States,2013,38.88
29462,"Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models","BACKGROUND: The phase 3 trial of the RTS,S/AS01 malaria vaccine candidate showed modest efficacy of the vaccine against Plasmodium falciparum malaria, but was not powered to assess mortality endpoints. Impact projections and cost-effectiveness estimates for longer timeframes than the trial follow-up and across a range of settings are needed to inform policy recommendations. We aimed to assess the public health impact and cost-effectiveness of routine use of the RTS,S/AS01 vaccine in African settings. METHODS: We compared four malaria transmission models and their predictions to assess vaccine cost-effectiveness and impact. We used trial data for follow-up of 32 months or longer to parameterise vaccine protection in the group aged 5-17 months. Estimates of cases, deaths, and disability-adjusted life-years (DALYs) averted were calculated over a 15 year time horizon for a range of levels of Plasmodium falciparum parasite prevalence in 2-10 year olds (PfPR2-10; range 3-65%). We considered two vaccine schedules: three doses at ages 6, 7.5, and 9 months (three-dose schedule, 90% coverage) and including a fourth dose at age 27 months (four-dose schedule, 72% coverage). We estimated cost-effectiveness in the presence of existing malaria interventions for vaccine prices of US$2-10 per dose. FINDINGS: In regions with a PfPR2-10 of 10-65%, RTS,S/AS01 is predicted to avert a median of 93,940 (range 20,490-126,540) clinical cases and 394 (127-708) deaths for the three-dose schedule, or 116,480 (31,450-160,410) clinical cases and 484 (189-859) deaths for the four-dose schedule, per 100,000 fully vaccinated children. A positive impact is also predicted at a PfPR2-10 of 5-10%, but there is little impact at a prevalence of lower than 3%. At $5 per dose and a PfPR2-10 of 10-65%, we estimated a median incremental cost-effectiveness ratio compared with current interventions of $30 (range 18-211) per clinical case averted and $80 (44-279) per DALY averted for the three-dose schedule, and of $25 (16-222) and $87 (48-244), respectively, for the four-dose schedule. Higher ICERs were estimated at low PfPR2-10 levels. INTERPRETATION: We predict a significant public health impact and high cost-effectiveness of the RTS,S/AS01 vaccine across a wide range of settings. Decisions about implementation will need to consider levels of malaria burden, the cost-effectiveness and coverage of other malaria interventions, health priorities, financing, and the capacity of the health system to deliver the vaccine. FUNDING: PATH Malaria Vaccine Initiative; Bill & Melinda Gates Foundation; Global Good Fund; Medical Research Council; UK Department for International Development; GAVI, the Vaccine Alliance; WHO.",2016-XX-20736,26549466,Lancet,Melissa A Penny,2016,387 / 10016,367-75,No,26549466,"Melissa A Penny; Robert Verity; Caitlin A Bever; Christophe Sauboin; Katya Galactionova; Stefan Flasche; Michael T White; Edward A Wenger; Nicolas Van de Velde; Peter Pemberton-Ross; Jamie T Griffin; Thomas A Smith; Philip A Eckhoff; Farzana Muhib; Mark Jit; Azra C Ghani; Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models, Lancet, 2016 Jan 23; 387(10016):0140-6736; 367-75",DALY,Ethiopia,Not Stated,Immunization,"RTS,S/AS01 malaria vaccine, 4 doses (cost $2 per dose) vs. Standard/Usual Care",Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,Not Stated,38,United States,2013,42.22
29463,Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis,"INTRODUCTION: There is an immense need for scaling-up neuropsychiatric care in low-income countries. Contextualized cost-effectiveness analyses (CEAs) provide relevant information for local policies. The aim of this study is to perform a contextualized CEA of neuropsychiatric interventions in Ethiopia and to illustrate expected population health and budget impacts across neuropsychiatric disorders. METHODS: A mathematical population model (PopMod) was used to estimate intervention costs and effectiveness. Existing variables from a previous WHO-CHOICE regional CEA model were substantially revised. Treatments for depression, schizophrenia, bipolar disorder and epilepsy were analysed. The best available local data on epidemiology, intervention efficacy, current and target coverage, resource prices and salaries were used. Data were obtained from expert opinion, local hospital information systems, the Ministry of Health and literature reviews. RESULTS: Treatment of epilepsy with a first generation antiepileptic drug is the most cost-effective treatment (US$ 321 per DALY adverted). Treatments for depression have mid-range values compared with other interventions (US$ 457-1026 per DALY adverted). Treatments for schizophrenia and bipolar disorders are least cost-effective (US$ 1168-3739 per DALY adverted). CONCLUSION: This analysis gives the Ethiopian government a comprehensive overview of the expected costs, effectiveness and cost-effectiveness of introducing basic neuropsychiatric interventions.",2015-01-01801,26491060,Health Policy Plan,Kirsten Bjerkreim Strand,2016,31 / 4,,No,26491060,"Kirsten Bjerkreim Strand; Dan Chisholm; Abebaw Fekadu; Kjell Arne Johansson; Charles N. Haas; Joan B. Rose; Charles P. Gerba; Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis, Health Policy Plan, 2016 May; 31(4):0268-1080",DALY,Ethiopia,Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Dep1: Older antidepressant (TCA) vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,383.25,United States,2013,425.78
29464,Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis,"INTRODUCTION: There is an immense need for scaling-up neuropsychiatric care in low-income countries. Contextualized cost-effectiveness analyses (CEAs) provide relevant information for local policies. The aim of this study is to perform a contextualized CEA of neuropsychiatric interventions in Ethiopia and to illustrate expected population health and budget impacts across neuropsychiatric disorders. METHODS: A mathematical population model (PopMod) was used to estimate intervention costs and effectiveness. Existing variables from a previous WHO-CHOICE regional CEA model were substantially revised. Treatments for depression, schizophrenia, bipolar disorder and epilepsy were analysed. The best available local data on epidemiology, intervention efficacy, current and target coverage, resource prices and salaries were used. Data were obtained from expert opinion, local hospital information systems, the Ministry of Health and literature reviews. RESULTS: Treatment of epilepsy with a first generation antiepileptic drug is the most cost-effective treatment (US$ 321 per DALY adverted). Treatments for depression have mid-range values compared with other interventions (US$ 457-1026 per DALY adverted). Treatments for schizophrenia and bipolar disorders are least cost-effective (US$ 1168-3739 per DALY adverted). CONCLUSION: This analysis gives the Ethiopian government a comprehensive overview of the expected costs, effectiveness and cost-effectiveness of introducing basic neuropsychiatric interventions.",2015-01-01801,26491060,Health Policy Plan,Kirsten Bjerkreim Strand,2016,31 / 4,,No,26491060,"Kirsten Bjerkreim Strand; Dan Chisholm; Abebaw Fekadu; Kjell Arne Johansson; Charles N. Haas; Joan B. Rose; Charles P. Gerba; Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis, Health Policy Plan, 2016 May; 31(4):0268-1080",DALY,Ethiopia,Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Dep2: Newer Antidepressants (SSRI) vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,372.74,United States,2013,414.1
29465,Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis,"INTRODUCTION: There is an immense need for scaling-up neuropsychiatric care in low-income countries. Contextualized cost-effectiveness analyses (CEAs) provide relevant information for local policies. The aim of this study is to perform a contextualized CEA of neuropsychiatric interventions in Ethiopia and to illustrate expected population health and budget impacts across neuropsychiatric disorders. METHODS: A mathematical population model (PopMod) was used to estimate intervention costs and effectiveness. Existing variables from a previous WHO-CHOICE regional CEA model were substantially revised. Treatments for depression, schizophrenia, bipolar disorder and epilepsy were analysed. The best available local data on epidemiology, intervention efficacy, current and target coverage, resource prices and salaries were used. Data were obtained from expert opinion, local hospital information systems, the Ministry of Health and literature reviews. RESULTS: Treatment of epilepsy with a first generation antiepileptic drug is the most cost-effective treatment (US$ 321 per DALY adverted). Treatments for depression have mid-range values compared with other interventions (US$ 457-1026 per DALY adverted). Treatments for schizophrenia and bipolar disorders are least cost-effective (US$ 1168-3739 per DALY adverted). CONCLUSION: This analysis gives the Ethiopian government a comprehensive overview of the expected costs, effectiveness and cost-effectiveness of introducing basic neuropsychiatric interventions.",2015-01-01801,26491060,Health Policy Plan,Kirsten Bjerkreim Strand,2016,31 / 4,,No,26491060,"Kirsten Bjerkreim Strand; Dan Chisholm; Abebaw Fekadu; Kjell Arne Johansson; Charles N. Haas; Joan B. Rose; Charles P. Gerba; Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis, Health Policy Plan, 2016 May; 31(4):0268-1080",DALY,Ethiopia,Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Dep3: Psychotherapy vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,1369.4,United States,2013,1521.38
29466,Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis,"INTRODUCTION: There is an immense need for scaling-up neuropsychiatric care in low-income countries. Contextualized cost-effectiveness analyses (CEAs) provide relevant information for local policies. The aim of this study is to perform a contextualized CEA of neuropsychiatric interventions in Ethiopia and to illustrate expected population health and budget impacts across neuropsychiatric disorders. METHODS: A mathematical population model (PopMod) was used to estimate intervention costs and effectiveness. Existing variables from a previous WHO-CHOICE regional CEA model were substantially revised. Treatments for depression, schizophrenia, bipolar disorder and epilepsy were analysed. The best available local data on epidemiology, intervention efficacy, current and target coverage, resource prices and salaries were used. Data were obtained from expert opinion, local hospital information systems, the Ministry of Health and literature reviews. RESULTS: Treatment of epilepsy with a first generation antiepileptic drug is the most cost-effective treatment (US$ 321 per DALY adverted). Treatments for depression have mid-range values compared with other interventions (US$ 457-1026 per DALY adverted). Treatments for schizophrenia and bipolar disorders are least cost-effective (US$ 1168-3739 per DALY adverted). CONCLUSION: This analysis gives the Ethiopian government a comprehensive overview of the expected costs, effectiveness and cost-effectiveness of introducing basic neuropsychiatric interventions.",2015-01-01801,26491060,Health Policy Plan,Kirsten Bjerkreim Strand,2016,31 / 4,,No,26491060,"Kirsten Bjerkreim Strand; Dan Chisholm; Abebaw Fekadu; Kjell Arne Johansson; Charles N. Haas; Joan B. Rose; Charles P. Gerba; Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis, Health Policy Plan, 2016 May; 31(4):0268-1080",DALY,Ethiopia,Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Dep4: Older antidepressants (TCA) and psychotherapy vs. Standard/Usual Care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,1190.58,United States,2013,1322.71
29467,Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis,"INTRODUCTION: There is an immense need for scaling-up neuropsychiatric care in low-income countries. Contextualized cost-effectiveness analyses (CEAs) provide relevant information for local policies. The aim of this study is to perform a contextualized CEA of neuropsychiatric interventions in Ethiopia and to illustrate expected population health and budget impacts across neuropsychiatric disorders. METHODS: A mathematical population model (PopMod) was used to estimate intervention costs and effectiveness. Existing variables from a previous WHO-CHOICE regional CEA model were substantially revised. Treatments for depression, schizophrenia, bipolar disorder and epilepsy were analysed. The best available local data on epidemiology, intervention efficacy, current and target coverage, resource prices and salaries were used. Data were obtained from expert opinion, local hospital information systems, the Ministry of Health and literature reviews. RESULTS: Treatment of epilepsy with a first generation antiepileptic drug is the most cost-effective treatment (US$ 321 per DALY adverted). Treatments for depression have mid-range values compared with other interventions (US$ 457-1026 per DALY adverted). Treatments for schizophrenia and bipolar disorders are least cost-effective (US$ 1168-3739 per DALY adverted). CONCLUSION: This analysis gives the Ethiopian government a comprehensive overview of the expected costs, effectiveness and cost-effectiveness of introducing basic neuropsychiatric interventions.",2015-01-01801,26491060,Health Policy Plan,Kirsten Bjerkreim Strand,2016,31 / 4,,No,26491060,"Kirsten Bjerkreim Strand; Dan Chisholm; Abebaw Fekadu; Kjell Arne Johansson; Charles N. Haas; Joan B. Rose; Charles P. Gerba; Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis, Health Policy Plan, 2016 May; 31(4):0268-1080",DALY,Ethiopia,Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Dep5: Newer antidepressants (selective serotonin re-uptake inhibitors) and psychotherapy vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,1025.33,United States,2013,1139.12
29468,Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis,"INTRODUCTION: There is an immense need for scaling-up neuropsychiatric care in low-income countries. Contextualized cost-effectiveness analyses (CEAs) provide relevant information for local policies. The aim of this study is to perform a contextualized CEA of neuropsychiatric interventions in Ethiopia and to illustrate expected population health and budget impacts across neuropsychiatric disorders. METHODS: A mathematical population model (PopMod) was used to estimate intervention costs and effectiveness. Existing variables from a previous WHO-CHOICE regional CEA model were substantially revised. Treatments for depression, schizophrenia, bipolar disorder and epilepsy were analysed. The best available local data on epidemiology, intervention efficacy, current and target coverage, resource prices and salaries were used. Data were obtained from expert opinion, local hospital information systems, the Ministry of Health and literature reviews. RESULTS: Treatment of epilepsy with a first generation antiepileptic drug is the most cost-effective treatment (US$ 321 per DALY adverted). Treatments for depression have mid-range values compared with other interventions (US$ 457-1026 per DALY adverted). Treatments for schizophrenia and bipolar disorders are least cost-effective (US$ 1168-3739 per DALY adverted). CONCLUSION: This analysis gives the Ethiopian government a comprehensive overview of the expected costs, effectiveness and cost-effectiveness of introducing basic neuropsychiatric interventions.",2015-01-01801,26491060,Health Policy Plan,Kirsten Bjerkreim Strand,2016,31 / 4,,No,26491060,"Kirsten Bjerkreim Strand; Dan Chisholm; Abebaw Fekadu; Kjell Arne Johansson; Charles N. Haas; Joan B. Rose; Charles P. Gerba; Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis, Health Policy Plan, 2016 May; 31(4):0268-1080",DALY,Ethiopia,Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Dep6: Maintenance: older antidepressants (TCA) and psychotherapy vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,607.39,United States,2013,674.8
29469,Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis,"INTRODUCTION: There is an immense need for scaling-up neuropsychiatric care in low-income countries. Contextualized cost-effectiveness analyses (CEAs) provide relevant information for local policies. The aim of this study is to perform a contextualized CEA of neuropsychiatric interventions in Ethiopia and to illustrate expected population health and budget impacts across neuropsychiatric disorders. METHODS: A mathematical population model (PopMod) was used to estimate intervention costs and effectiveness. Existing variables from a previous WHO-CHOICE regional CEA model were substantially revised. Treatments for depression, schizophrenia, bipolar disorder and epilepsy were analysed. The best available local data on epidemiology, intervention efficacy, current and target coverage, resource prices and salaries were used. Data were obtained from expert opinion, local hospital information systems, the Ministry of Health and literature reviews. RESULTS: Treatment of epilepsy with a first generation antiepileptic drug is the most cost-effective treatment (US$ 321 per DALY adverted). Treatments for depression have mid-range values compared with other interventions (US$ 457-1026 per DALY adverted). Treatments for schizophrenia and bipolar disorders are least cost-effective (US$ 1168-3739 per DALY adverted). CONCLUSION: This analysis gives the Ethiopian government a comprehensive overview of the expected costs, effectiveness and cost-effectiveness of introducing basic neuropsychiatric interventions.",2015-01-01801,26491060,Health Policy Plan,Kirsten Bjerkreim Strand,2016,31 / 4,,No,26491060,"Kirsten Bjerkreim Strand; Dan Chisholm; Abebaw Fekadu; Kjell Arne Johansson; Charles N. Haas; Joan B. Rose; Charles P. Gerba; Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis, Health Policy Plan, 2016 May; 31(4):0268-1080",DALY,Ethiopia,Not Stated,"Health Education or Behavior, Pharmaceutical, Other",Dep7: Maintenance: Newer antidepressants (selective serotonin re-uptake inhibitors) and psychotherapy vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,609.84,United States,2013,677.52
29470,Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis,"INTRODUCTION: There is an immense need for scaling-up neuropsychiatric care in low-income countries. Contextualized cost-effectiveness analyses (CEAs) provide relevant information for local policies. The aim of this study is to perform a contextualized CEA of neuropsychiatric interventions in Ethiopia and to illustrate expected population health and budget impacts across neuropsychiatric disorders. METHODS: A mathematical population model (PopMod) was used to estimate intervention costs and effectiveness. Existing variables from a previous WHO-CHOICE regional CEA model were substantially revised. Treatments for depression, schizophrenia, bipolar disorder and epilepsy were analysed. The best available local data on epidemiology, intervention efficacy, current and target coverage, resource prices and salaries were used. Data were obtained from expert opinion, local hospital information systems, the Ministry of Health and literature reviews. RESULTS: Treatment of epilepsy with a first generation antiepileptic drug is the most cost-effective treatment (US$ 321 per DALY adverted). Treatments for depression have mid-range values compared with other interventions (US$ 457-1026 per DALY adverted). Treatments for schizophrenia and bipolar disorders are least cost-effective (US$ 1168-3739 per DALY adverted). CONCLUSION: This analysis gives the Ethiopian government a comprehensive overview of the expected costs, effectiveness and cost-effectiveness of introducing basic neuropsychiatric interventions.",2015-01-01801,26491060,Health Policy Plan,Kirsten Bjerkreim Strand,2016,31 / 4,,No,26491060,"Kirsten Bjerkreim Strand; Dan Chisholm; Abebaw Fekadu; Kjell Arne Johansson; Charles N. Haas; Joan B. Rose; Charles P. Gerba; Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis, Health Policy Plan, 2016 May; 31(4):0268-1080",DALY,Ethiopia,Not Stated,"Health Education or Behavior, Pharmaceutical, Other",SCZ1: Typical antipsychotics vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,2908.09,United States,2013,3230.84
29471,Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis,"INTRODUCTION: There is an immense need for scaling-up neuropsychiatric care in low-income countries. Contextualized cost-effectiveness analyses (CEAs) provide relevant information for local policies. The aim of this study is to perform a contextualized CEA of neuropsychiatric interventions in Ethiopia and to illustrate expected population health and budget impacts across neuropsychiatric disorders. METHODS: A mathematical population model (PopMod) was used to estimate intervention costs and effectiveness. Existing variables from a previous WHO-CHOICE regional CEA model were substantially revised. Treatments for depression, schizophrenia, bipolar disorder and epilepsy were analysed. The best available local data on epidemiology, intervention efficacy, current and target coverage, resource prices and salaries were used. Data were obtained from expert opinion, local hospital information systems, the Ministry of Health and literature reviews. RESULTS: Treatment of epilepsy with a first generation antiepileptic drug is the most cost-effective treatment (US$ 321 per DALY adverted). Treatments for depression have mid-range values compared with other interventions (US$ 457-1026 per DALY adverted). Treatments for schizophrenia and bipolar disorders are least cost-effective (US$ 1168-3739 per DALY adverted). CONCLUSION: This analysis gives the Ethiopian government a comprehensive overview of the expected costs, effectiveness and cost-effectiveness of introducing basic neuropsychiatric interventions.",2015-01-01801,26491060,Health Policy Plan,Kirsten Bjerkreim Strand,2016,31 / 4,,No,26491060,"Kirsten Bjerkreim Strand; Dan Chisholm; Abebaw Fekadu; Kjell Arne Johansson; Charles N. Haas; Joan B. Rose; Charles P. Gerba; Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis, Health Policy Plan, 2016 May; 31(4):0268-1080",DALY,Ethiopia,Not Stated,"Health Education or Behavior, Pharmaceutical, Other",SCZ2: Atypical antipsychotics vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,2390.42,United States,2013,2655.71
29472,Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis,"INTRODUCTION: There is an immense need for scaling-up neuropsychiatric care in low-income countries. Contextualized cost-effectiveness analyses (CEAs) provide relevant information for local policies. The aim of this study is to perform a contextualized CEA of neuropsychiatric interventions in Ethiopia and to illustrate expected population health and budget impacts across neuropsychiatric disorders. METHODS: A mathematical population model (PopMod) was used to estimate intervention costs and effectiveness. Existing variables from a previous WHO-CHOICE regional CEA model were substantially revised. Treatments for depression, schizophrenia, bipolar disorder and epilepsy were analysed. The best available local data on epidemiology, intervention efficacy, current and target coverage, resource prices and salaries were used. Data were obtained from expert opinion, local hospital information systems, the Ministry of Health and literature reviews. RESULTS: Treatment of epilepsy with a first generation antiepileptic drug is the most cost-effective treatment (US$ 321 per DALY adverted). Treatments for depression have mid-range values compared with other interventions (US$ 457-1026 per DALY adverted). Treatments for schizophrenia and bipolar disorders are least cost-effective (US$ 1168-3739 per DALY adverted). CONCLUSION: This analysis gives the Ethiopian government a comprehensive overview of the expected costs, effectiveness and cost-effectiveness of introducing basic neuropsychiatric interventions.",2015-01-01801,26491060,Health Policy Plan,Kirsten Bjerkreim Strand,2016,31 / 4,,No,26491060,"Kirsten Bjerkreim Strand; Dan Chisholm; Abebaw Fekadu; Kjell Arne Johansson; Charles N. Haas; Joan B. Rose; Charles P. Gerba; Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis, Health Policy Plan, 2016 May; 31(4):0268-1080",DALY,Ethiopia,Not Stated,"Health Education or Behavior, Pharmaceutical, Other",SCZ3: Typical antipsychotics plus psychosocial treatment vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,1689.37,United States,2013,1876.86
29473,Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis,"INTRODUCTION: There is an immense need for scaling-up neuropsychiatric care in low-income countries. Contextualized cost-effectiveness analyses (CEAs) provide relevant information for local policies. The aim of this study is to perform a contextualized CEA of neuropsychiatric interventions in Ethiopia and to illustrate expected population health and budget impacts across neuropsychiatric disorders. METHODS: A mathematical population model (PopMod) was used to estimate intervention costs and effectiveness. Existing variables from a previous WHO-CHOICE regional CEA model were substantially revised. Treatments for depression, schizophrenia, bipolar disorder and epilepsy were analysed. The best available local data on epidemiology, intervention efficacy, current and target coverage, resource prices and salaries were used. Data were obtained from expert opinion, local hospital information systems, the Ministry of Health and literature reviews. RESULTS: Treatment of epilepsy with a first generation antiepileptic drug is the most cost-effective treatment (US$ 321 per DALY adverted). Treatments for depression have mid-range values compared with other interventions (US$ 457-1026 per DALY adverted). Treatments for schizophrenia and bipolar disorders are least cost-effective (US$ 1168-3739 per DALY adverted). CONCLUSION: This analysis gives the Ethiopian government a comprehensive overview of the expected costs, effectiveness and cost-effectiveness of introducing basic neuropsychiatric interventions.",2015-01-01801,26491060,Health Policy Plan,Kirsten Bjerkreim Strand,2016,31 / 4,,No,26491060,"Kirsten Bjerkreim Strand; Dan Chisholm; Abebaw Fekadu; Kjell Arne Johansson; Charles N. Haas; Joan B. Rose; Charles P. Gerba; Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis, Health Policy Plan, 2016 May; 31(4):0268-1080",DALY,Ethiopia,Not Stated,"Health Education or Behavior, Pharmaceutical, Other",SCZ4: Atypical antipsychotics plus psychosocial treatment vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,1493.93,United States,2013,1659.73
29474,Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis,"INTRODUCTION: There is an immense need for scaling-up neuropsychiatric care in low-income countries. Contextualized cost-effectiveness analyses (CEAs) provide relevant information for local policies. The aim of this study is to perform a contextualized CEA of neuropsychiatric interventions in Ethiopia and to illustrate expected population health and budget impacts across neuropsychiatric disorders. METHODS: A mathematical population model (PopMod) was used to estimate intervention costs and effectiveness. Existing variables from a previous WHO-CHOICE regional CEA model were substantially revised. Treatments for depression, schizophrenia, bipolar disorder and epilepsy were analysed. The best available local data on epidemiology, intervention efficacy, current and target coverage, resource prices and salaries were used. Data were obtained from expert opinion, local hospital information systems, the Ministry of Health and literature reviews. RESULTS: Treatment of epilepsy with a first generation antiepileptic drug is the most cost-effective treatment (US$ 321 per DALY adverted). Treatments for depression have mid-range values compared with other interventions (US$ 457-1026 per DALY adverted). Treatments for schizophrenia and bipolar disorders are least cost-effective (US$ 1168-3739 per DALY adverted). CONCLUSION: This analysis gives the Ethiopian government a comprehensive overview of the expected costs, effectiveness and cost-effectiveness of introducing basic neuropsychiatric interventions.",2015-01-01801,26491060,Health Policy Plan,Kirsten Bjerkreim Strand,2016,31 / 4,,No,26491060,"Kirsten Bjerkreim Strand; Dan Chisholm; Abebaw Fekadu; Kjell Arne Johansson; Charles N. Haas; Joan B. Rose; Charles P. Gerba; Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis, Health Policy Plan, 2016 May; 31(4):0268-1080",DALY,Ethiopia,Not Stated,"Health Education or Behavior, Pharmaceutical, Other",SCZ5: Case id manager: Typical antipsychotics and psychosocial treatment vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,1639.47,United States,2013,1821.42
29475,Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis,"INTRODUCTION: There is an immense need for scaling-up neuropsychiatric care in low-income countries. Contextualized cost-effectiveness analyses (CEAs) provide relevant information for local policies. The aim of this study is to perform a contextualized CEA of neuropsychiatric interventions in Ethiopia and to illustrate expected population health and budget impacts across neuropsychiatric disorders. METHODS: A mathematical population model (PopMod) was used to estimate intervention costs and effectiveness. Existing variables from a previous WHO-CHOICE regional CEA model were substantially revised. Treatments for depression, schizophrenia, bipolar disorder and epilepsy were analysed. The best available local data on epidemiology, intervention efficacy, current and target coverage, resource prices and salaries were used. Data were obtained from expert opinion, local hospital information systems, the Ministry of Health and literature reviews. RESULTS: Treatment of epilepsy with a first generation antiepileptic drug is the most cost-effective treatment (US$ 321 per DALY adverted). Treatments for depression have mid-range values compared with other interventions (US$ 457-1026 per DALY adverted). Treatments for schizophrenia and bipolar disorders are least cost-effective (US$ 1168-3739 per DALY adverted). CONCLUSION: This analysis gives the Ethiopian government a comprehensive overview of the expected costs, effectiveness and cost-effectiveness of introducing basic neuropsychiatric interventions.",2015-01-01801,26491060,Health Policy Plan,Kirsten Bjerkreim Strand,2016,31 / 4,,No,26491060,"Kirsten Bjerkreim Strand; Dan Chisholm; Abebaw Fekadu; Kjell Arne Johansson; Charles N. Haas; Joan B. Rose; Charles P. Gerba; Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis, Health Policy Plan, 2016 May; 31(4):0268-1080",DALY,Ethiopia,Not Stated,"Health Education or Behavior, Pharmaceutical, Other",SCZ6: Case id manager: Atypical antipsychotics and psychosocial treatment vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,1632.74,United States,2013,1813.94
29476,Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis,"INTRODUCTION: There is an immense need for scaling-up neuropsychiatric care in low-income countries. Contextualized cost-effectiveness analyses (CEAs) provide relevant information for local policies. The aim of this study is to perform a contextualized CEA of neuropsychiatric interventions in Ethiopia and to illustrate expected population health and budget impacts across neuropsychiatric disorders. METHODS: A mathematical population model (PopMod) was used to estimate intervention costs and effectiveness. Existing variables from a previous WHO-CHOICE regional CEA model were substantially revised. Treatments for depression, schizophrenia, bipolar disorder and epilepsy were analysed. The best available local data on epidemiology, intervention efficacy, current and target coverage, resource prices and salaries were used. Data were obtained from expert opinion, local hospital information systems, the Ministry of Health and literature reviews. RESULTS: Treatment of epilepsy with a first generation antiepileptic drug is the most cost-effective treatment (US$ 321 per DALY adverted). Treatments for depression have mid-range values compared with other interventions (US$ 457-1026 per DALY adverted). Treatments for schizophrenia and bipolar disorders are least cost-effective (US$ 1168-3739 per DALY adverted). CONCLUSION: This analysis gives the Ethiopian government a comprehensive overview of the expected costs, effectiveness and cost-effectiveness of introducing basic neuropsychiatric interventions.",2015-01-01801,26491060,Health Policy Plan,Kirsten Bjerkreim Strand,2016,31 / 4,,No,26491060,"Kirsten Bjerkreim Strand; Dan Chisholm; Abebaw Fekadu; Kjell Arne Johansson; Charles N. Haas; Joan B. Rose; Charles P. Gerba; Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis, Health Policy Plan, 2016 May; 31(4):0268-1080",DALY,Ethiopia,Not Stated,"Health Education or Behavior, Pharmaceutical, Other",BIP1: Older mood stabilizer (Lithium) vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,820.03,United States,2013,911.04
29477,Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis,"INTRODUCTION: There is an immense need for scaling-up neuropsychiatric care in low-income countries. Contextualized cost-effectiveness analyses (CEAs) provide relevant information for local policies. The aim of this study is to perform a contextualized CEA of neuropsychiatric interventions in Ethiopia and to illustrate expected population health and budget impacts across neuropsychiatric disorders. METHODS: A mathematical population model (PopMod) was used to estimate intervention costs and effectiveness. Existing variables from a previous WHO-CHOICE regional CEA model were substantially revised. Treatments for depression, schizophrenia, bipolar disorder and epilepsy were analysed. The best available local data on epidemiology, intervention efficacy, current and target coverage, resource prices and salaries were used. Data were obtained from expert opinion, local hospital information systems, the Ministry of Health and literature reviews. RESULTS: Treatment of epilepsy with a first generation antiepileptic drug is the most cost-effective treatment (US$ 321 per DALY adverted). Treatments for depression have mid-range values compared with other interventions (US$ 457-1026 per DALY adverted). Treatments for schizophrenia and bipolar disorders are least cost-effective (US$ 1168-3739 per DALY adverted). CONCLUSION: This analysis gives the Ethiopian government a comprehensive overview of the expected costs, effectiveness and cost-effectiveness of introducing basic neuropsychiatric interventions.",2015-01-01801,26491060,Health Policy Plan,Kirsten Bjerkreim Strand,2016,31 / 4,,No,26491060,"Kirsten Bjerkreim Strand; Dan Chisholm; Abebaw Fekadu; Kjell Arne Johansson; Charles N. Haas; Joan B. Rose; Charles P. Gerba; Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis, Health Policy Plan, 2016 May; 31(4):0268-1080",DALY,Ethiopia,Not Stated,"Health Education or Behavior, Pharmaceutical, Other",BIP2: Newer mood stabilizer (Valproate) vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,857.36,United States,2013,952.51
29478,Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis,"INTRODUCTION: There is an immense need for scaling-up neuropsychiatric care in low-income countries. Contextualized cost-effectiveness analyses (CEAs) provide relevant information for local policies. The aim of this study is to perform a contextualized CEA of neuropsychiatric interventions in Ethiopia and to illustrate expected population health and budget impacts across neuropsychiatric disorders. METHODS: A mathematical population model (PopMod) was used to estimate intervention costs and effectiveness. Existing variables from a previous WHO-CHOICE regional CEA model were substantially revised. Treatments for depression, schizophrenia, bipolar disorder and epilepsy were analysed. The best available local data on epidemiology, intervention efficacy, current and target coverage, resource prices and salaries were used. Data were obtained from expert opinion, local hospital information systems, the Ministry of Health and literature reviews. RESULTS: Treatment of epilepsy with a first generation antiepileptic drug is the most cost-effective treatment (US$ 321 per DALY adverted). Treatments for depression have mid-range values compared with other interventions (US$ 457-1026 per DALY adverted). Treatments for schizophrenia and bipolar disorders are least cost-effective (US$ 1168-3739 per DALY adverted). CONCLUSION: This analysis gives the Ethiopian government a comprehensive overview of the expected costs, effectiveness and cost-effectiveness of introducing basic neuropsychiatric interventions.",2015-01-01801,26491060,Health Policy Plan,Kirsten Bjerkreim Strand,2016,31 / 4,,No,26491060,"Kirsten Bjerkreim Strand; Dan Chisholm; Abebaw Fekadu; Kjell Arne Johansson; Charles N. Haas; Joan B. Rose; Charles P. Gerba; Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis, Health Policy Plan, 2016 May; 31(4):0268-1080",DALY,Ethiopia,Not Stated,"Health Education or Behavior, Pharmaceutical, Other",BIP3: Older Mood Stabilizer (Lithium) plus psychosocial treatment vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,861.06,United States,2013,956.62
29479,Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis,"INTRODUCTION: There is an immense need for scaling-up neuropsychiatric care in low-income countries. Contextualized cost-effectiveness analyses (CEAs) provide relevant information for local policies. The aim of this study is to perform a contextualized CEA of neuropsychiatric interventions in Ethiopia and to illustrate expected population health and budget impacts across neuropsychiatric disorders. METHODS: A mathematical population model (PopMod) was used to estimate intervention costs and effectiveness. Existing variables from a previous WHO-CHOICE regional CEA model were substantially revised. Treatments for depression, schizophrenia, bipolar disorder and epilepsy were analysed. The best available local data on epidemiology, intervention efficacy, current and target coverage, resource prices and salaries were used. Data were obtained from expert opinion, local hospital information systems, the Ministry of Health and literature reviews. RESULTS: Treatment of epilepsy with a first generation antiepileptic drug is the most cost-effective treatment (US$ 321 per DALY adverted). Treatments for depression have mid-range values compared with other interventions (US$ 457-1026 per DALY adverted). Treatments for schizophrenia and bipolar disorders are least cost-effective (US$ 1168-3739 per DALY adverted). CONCLUSION: This analysis gives the Ethiopian government a comprehensive overview of the expected costs, effectiveness and cost-effectiveness of introducing basic neuropsychiatric interventions.",2015-01-01801,26491060,Health Policy Plan,Kirsten Bjerkreim Strand,2016,31 / 4,,No,26491060,"Kirsten Bjerkreim Strand; Dan Chisholm; Abebaw Fekadu; Kjell Arne Johansson; Charles N. Haas; Joan B. Rose; Charles P. Gerba; Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis, Health Policy Plan, 2016 May; 31(4):0268-1080",DALY,Ethiopia,Not Stated,"Health Education or Behavior, Pharmaceutical, Other",BIP4: Newer Mood Stabilizer (Valproate) plus psychosocial treatment vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,888.36,United States,2013,986.95
29480,Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis,"INTRODUCTION: There is an immense need for scaling-up neuropsychiatric care in low-income countries. Contextualized cost-effectiveness analyses (CEAs) provide relevant information for local policies. The aim of this study is to perform a contextualized CEA of neuropsychiatric interventions in Ethiopia and to illustrate expected population health and budget impacts across neuropsychiatric disorders. METHODS: A mathematical population model (PopMod) was used to estimate intervention costs and effectiveness. Existing variables from a previous WHO-CHOICE regional CEA model were substantially revised. Treatments for depression, schizophrenia, bipolar disorder and epilepsy were analysed. The best available local data on epidemiology, intervention efficacy, current and target coverage, resource prices and salaries were used. Data were obtained from expert opinion, local hospital information systems, the Ministry of Health and literature reviews. RESULTS: Treatment of epilepsy with a first generation antiepileptic drug is the most cost-effective treatment (US$ 321 per DALY adverted). Treatments for depression have mid-range values compared with other interventions (US$ 457-1026 per DALY adverted). Treatments for schizophrenia and bipolar disorders are least cost-effective (US$ 1168-3739 per DALY adverted). CONCLUSION: This analysis gives the Ethiopian government a comprehensive overview of the expected costs, effectiveness and cost-effectiveness of introducing basic neuropsychiatric interventions.",2015-01-01801,26491060,Health Policy Plan,Kirsten Bjerkreim Strand,2016,31 / 4,,No,26491060,"Kirsten Bjerkreim Strand; Dan Chisholm; Abebaw Fekadu; Kjell Arne Johansson; Charles N. Haas; Joan B. Rose; Charles P. Gerba; Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis, Health Policy Plan, 2016 May; 31(4):0268-1080",DALY,Ethiopia,Not Stated,"Health Education or Behavior, Pharmaceutical, Other",EPI1: Older Antiepileptic treatment (Phenobarbital) vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,137.42,United States,2013,152.67
29481,Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis,"INTRODUCTION: There is an immense need for scaling-up neuropsychiatric care in low-income countries. Contextualized cost-effectiveness analyses (CEAs) provide relevant information for local policies. The aim of this study is to perform a contextualized CEA of neuropsychiatric interventions in Ethiopia and to illustrate expected population health and budget impacts across neuropsychiatric disorders. METHODS: A mathematical population model (PopMod) was used to estimate intervention costs and effectiveness. Existing variables from a previous WHO-CHOICE regional CEA model were substantially revised. Treatments for depression, schizophrenia, bipolar disorder and epilepsy were analysed. The best available local data on epidemiology, intervention efficacy, current and target coverage, resource prices and salaries were used. Data were obtained from expert opinion, local hospital information systems, the Ministry of Health and literature reviews. RESULTS: Treatment of epilepsy with a first generation antiepileptic drug is the most cost-effective treatment (US$ 321 per DALY adverted). Treatments for depression have mid-range values compared with other interventions (US$ 457-1026 per DALY adverted). Treatments for schizophrenia and bipolar disorders are least cost-effective (US$ 1168-3739 per DALY adverted). CONCLUSION: This analysis gives the Ethiopian government a comprehensive overview of the expected costs, effectiveness and cost-effectiveness of introducing basic neuropsychiatric interventions.",2015-01-01801,26491060,Health Policy Plan,Kirsten Bjerkreim Strand,2016,31 / 4,,No,26491060,"Kirsten Bjerkreim Strand; Dan Chisholm; Abebaw Fekadu; Kjell Arne Johansson; Charles N. Haas; Joan B. Rose; Charles P. Gerba; Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis, Health Policy Plan, 2016 May; 31(4):0268-1080",DALY,Ethiopia,Not Stated,"Health Education or Behavior, Pharmaceutical, Other",EPI2: Newer antiepileptic treatment (Carbomazepine) vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,3.00,3.00,298.89,United States,2013,332.07
29482,Eliminating artificial trans fatty acids in Argentina: estimated effects on the burden of coronary heart disease and costs,"OBJECTIVE: To estimate the impact of Argentine policies to reduce trans fatty acids (TFA) on coronary heart disease (CHD), disability-adjusted life years (DALYs) and associated health-care costs. METHODS: We estimated the baseline intake of TFA before 2004 to be 1.5% of total energy intake. We built a policy model including baseline intake of TFA, the oils and fats used to replace artificial TFAs, the clinical effect of reducing artificial TFAs and the costs and DALYs saved due to averted CHD events. To calculate the percentage of reduction of CHD, we calculated CHD risks on a population-based sample before and after implementation. The effect of the policies was modelled in three ways, based on projected changes: (i) in plasma lipid profiles; (ii) in lipid and inflammatory biomarkers; and (iii) the results of prospective cohort studies. We also estimated the present economic value of DALYs and associated health-care costs of coronary heart disease averted. FINDINGS: We estimated that projected changes in lipid profile would avert 301 deaths, 1066 acute CHD events, 5237 DALYs and 17 million United States dollars (US$) in health-care costs annually. Based on the adverse effects of TFA intake reported in prospective cohort studies, 1517 deaths, 5373 acute CHD events, 26 394 DALYs and US$ 87 million would be averted annually. CONCLUSION: Even under the most conservative scenario, reduction of TFA intake had a substantial effect on public health. These findings will help inform decision-makers in Argentina and other countries on the potential public health and economic impact of this policy.",2015-99-20944,26478625,Bull World Health Organ,Adolfo Rubinstein,2015,93 / 9,614-22,No,26478625,"Adolfo Rubinstein; Natalia Elorriaga; Osvaldo U Garay; Rosana Poggio; Joaquin Caporale; Maria G Matta; Federico Augustovski; Andres Pichon-Riviere; Dariush Mozaffarian; Eliminating artificial trans fatty acids in Argentina: estimated effects on the burden of coronary heart disease and costs, Bull World Health Organ, 2015 Sep 1; 93(9):0042-9686; 614-22",DALY,Argentina,Not Stated,"Health Education or Behavior, Legislation / Regulation, Other",Reduction of artificial trans fatty acids in food through alternative substitution (sunflower oil) vs. current consumption of trans fatty acid (1.5% of energy consumption),Not Stated,40 Years,19 Years,"Female, Male",Full,,5.00,5.00,Not Stated,United States,2012,Not Stated
29483,Surgery and Obstetric Care are Highly Cost-Effective Interventions in a Sub-Saharan African District Hospital: A Three-Month Single-Institution Study of Surgical Costs and Outcomes,"BACKGROUND: The Lancet recently sponsored a commission examining the role of surgery in global health. There is a paucity of published information on the cost-effectiveness of surgery in low- and middle-income countries, a key metric in the prioritisation of limited resources. METHODS: All patients undergoing emergency laparotomy, elective and emergency inguinal hernia repair, elective and emergency caesarean section, amputation, fracture manipulation, or fracture fixation over a 3 months period in a single district African hospital were assessed. World Health Organisation global burden of disease (GBD) methodology was used to calculate the disability-adjusted life years (DALYs) saved for each patient (using global and local life expectancy). Fully loaded costs were calculated for each patient's care and providing the overall surgical service. Cost-effectiveness was calculated in year 2012 US$ per DALY saved for each procedure and overall. RESULTS: A total of 428 patients were included, with an overall cost-effectiveness of $10.70 per DALY averted. The cost-effectiveness of individual procedures (global life expectancy) was: Amputation-$17.66; Emergency caesarean section-$7.42; Elective caesarean section-$20.50; Emergency laparotomy-$8.62; Elective hernia repair-$15.26; Emergency hernia repair-$4.36; Fracture/dislocation reduction-$69.03; Fracture/dislocation fixation-$225.89. CONCLUSIONS: Surgery is a highly cost-effective healthcare measure in the setting of an African district hospital. The presented outcomes demonstrate that surgery is on a par with better-recognised and funded interventions such as HIV anti-retrovirals, malaria prevention and diarrhoea treatment. There are recognised limitations with the GBD methodology used here; however, this remains the best way to investigate the cost-effectiveness of health interventions. This study provides useful information on an, at present, under-studied field.",2016-XX-20973,26470700,World J Surg,Geoffrey Roberts,2016,40 / 1,14-20,No,26470700,"Geoffrey Roberts; Charlotte Roberts; Amy Jamieson; Caris Grimes; Gemma Conn; Robert Bleichrodt; Surgery and Obstetric Care are Highly Cost-Effective Interventions in a Sub-Saharan African District Hospital: A Three-Month Single-Institution Study of Surgical Costs and Outcomes, World J Surg, 2016 Jan; 40(1):0364-2313; 14-20",DALY,Zambia,Not Stated,"Medical Procedure, Surgical",Amputation vs. None,"hospitalized, undergoing surgery",Not Stated,Not Stated,"Female, Male",Full,,3.00,Not Stated,26.92,United States,2012,30.35
29484,Surgery and Obstetric Care are Highly Cost-Effective Interventions in a Sub-Saharan African District Hospital: A Three-Month Single-Institution Study of Surgical Costs and Outcomes,"BACKGROUND: The Lancet recently sponsored a commission examining the role of surgery in global health. There is a paucity of published information on the cost-effectiveness of surgery in low- and middle-income countries, a key metric in the prioritisation of limited resources. METHODS: All patients undergoing emergency laparotomy, elective and emergency inguinal hernia repair, elective and emergency caesarean section, amputation, fracture manipulation, or fracture fixation over a 3 months period in a single district African hospital were assessed. World Health Organisation global burden of disease (GBD) methodology was used to calculate the disability-adjusted life years (DALYs) saved for each patient (using global and local life expectancy). Fully loaded costs were calculated for each patient's care and providing the overall surgical service. Cost-effectiveness was calculated in year 2012 US$ per DALY saved for each procedure and overall. RESULTS: A total of 428 patients were included, with an overall cost-effectiveness of $10.70 per DALY averted. The cost-effectiveness of individual procedures (global life expectancy) was: Amputation-$17.66; Emergency caesarean section-$7.42; Elective caesarean section-$20.50; Emergency laparotomy-$8.62; Elective hernia repair-$15.26; Emergency hernia repair-$4.36; Fracture/dislocation reduction-$69.03; Fracture/dislocation fixation-$225.89. CONCLUSIONS: Surgery is a highly cost-effective healthcare measure in the setting of an African district hospital. The presented outcomes demonstrate that surgery is on a par with better-recognised and funded interventions such as HIV anti-retrovirals, malaria prevention and diarrhoea treatment. There are recognised limitations with the GBD methodology used here; however, this remains the best way to investigate the cost-effectiveness of health interventions. This study provides useful information on an, at present, under-studied field.",2016-XX-20973,26470700,World J Surg,Geoffrey Roberts,2016,40 / 1,14-20,No,26470700,"Geoffrey Roberts; Charlotte Roberts; Amy Jamieson; Caris Grimes; Gemma Conn; Robert Bleichrodt; Surgery and Obstetric Care are Highly Cost-Effective Interventions in a Sub-Saharan African District Hospital: A Three-Month Single-Institution Study of Surgical Costs and Outcomes, World J Surg, 2016 Jan; 40(1):0364-2313; 14-20",DALY,Zambia,Not Stated,"Medical Procedure, Surgical",Emergency caesarian section vs. None,pregnant,Not Stated,Not Stated,Female,Full,,3.00,Not Stated,11.07,United States,2012,12.48
29485,Surgery and Obstetric Care are Highly Cost-Effective Interventions in a Sub-Saharan African District Hospital: A Three-Month Single-Institution Study of Surgical Costs and Outcomes,"BACKGROUND: The Lancet recently sponsored a commission examining the role of surgery in global health. There is a paucity of published information on the cost-effectiveness of surgery in low- and middle-income countries, a key metric in the prioritisation of limited resources. METHODS: All patients undergoing emergency laparotomy, elective and emergency inguinal hernia repair, elective and emergency caesarean section, amputation, fracture manipulation, or fracture fixation over a 3 months period in a single district African hospital were assessed. World Health Organisation global burden of disease (GBD) methodology was used to calculate the disability-adjusted life years (DALYs) saved for each patient (using global and local life expectancy). Fully loaded costs were calculated for each patient's care and providing the overall surgical service. Cost-effectiveness was calculated in year 2012 US$ per DALY saved for each procedure and overall. RESULTS: A total of 428 patients were included, with an overall cost-effectiveness of $10.70 per DALY averted. The cost-effectiveness of individual procedures (global life expectancy) was: Amputation-$17.66; Emergency caesarean section-$7.42; Elective caesarean section-$20.50; Emergency laparotomy-$8.62; Elective hernia repair-$15.26; Emergency hernia repair-$4.36; Fracture/dislocation reduction-$69.03; Fracture/dislocation fixation-$225.89. CONCLUSIONS: Surgery is a highly cost-effective healthcare measure in the setting of an African district hospital. The presented outcomes demonstrate that surgery is on a par with better-recognised and funded interventions such as HIV anti-retrovirals, malaria prevention and diarrhoea treatment. There are recognised limitations with the GBD methodology used here; however, this remains the best way to investigate the cost-effectiveness of health interventions. This study provides useful information on an, at present, under-studied field.",2016-XX-20973,26470700,World J Surg,Geoffrey Roberts,2016,40 / 1,14-20,No,26470700,"Geoffrey Roberts; Charlotte Roberts; Amy Jamieson; Caris Grimes; Gemma Conn; Robert Bleichrodt; Surgery and Obstetric Care are Highly Cost-Effective Interventions in a Sub-Saharan African District Hospital: A Three-Month Single-Institution Study of Surgical Costs and Outcomes, World J Surg, 2016 Jan; 40(1):0364-2313; 14-20",DALY,Zambia,Not Stated,"Medical Procedure, Surgical",Elective caesarian section vs. None,pregnant,Not Stated,Not Stated,Female,Full,,3.00,Not Stated,30.61,United States,2012,34.51
29486,Surgery and Obstetric Care are Highly Cost-Effective Interventions in a Sub-Saharan African District Hospital: A Three-Month Single-Institution Study of Surgical Costs and Outcomes,"BACKGROUND: The Lancet recently sponsored a commission examining the role of surgery in global health. There is a paucity of published information on the cost-effectiveness of surgery in low- and middle-income countries, a key metric in the prioritisation of limited resources. METHODS: All patients undergoing emergency laparotomy, elective and emergency inguinal hernia repair, elective and emergency caesarean section, amputation, fracture manipulation, or fracture fixation over a 3 months period in a single district African hospital were assessed. World Health Organisation global burden of disease (GBD) methodology was used to calculate the disability-adjusted life years (DALYs) saved for each patient (using global and local life expectancy). Fully loaded costs were calculated for each patient's care and providing the overall surgical service. Cost-effectiveness was calculated in year 2012 US$ per DALY saved for each procedure and overall. RESULTS: A total of 428 patients were included, with an overall cost-effectiveness of $10.70 per DALY averted. The cost-effectiveness of individual procedures (global life expectancy) was: Amputation-$17.66; Emergency caesarean section-$7.42; Elective caesarean section-$20.50; Emergency laparotomy-$8.62; Elective hernia repair-$15.26; Emergency hernia repair-$4.36; Fracture/dislocation reduction-$69.03; Fracture/dislocation fixation-$225.89. CONCLUSIONS: Surgery is a highly cost-effective healthcare measure in the setting of an African district hospital. The presented outcomes demonstrate that surgery is on a par with better-recognised and funded interventions such as HIV anti-retrovirals, malaria prevention and diarrhoea treatment. There are recognised limitations with the GBD methodology used here; however, this remains the best way to investigate the cost-effectiveness of health interventions. This study provides useful information on an, at present, under-studied field.",2016-XX-20973,26470700,World J Surg,Geoffrey Roberts,2016,40 / 1,14-20,No,26470700,"Geoffrey Roberts; Charlotte Roberts; Amy Jamieson; Caris Grimes; Gemma Conn; Robert Bleichrodt; Surgery and Obstetric Care are Highly Cost-Effective Interventions in a Sub-Saharan African District Hospital: A Three-Month Single-Institution Study of Surgical Costs and Outcomes, World J Surg, 2016 Jan; 40(1):0364-2313; 14-20",DALY,Zambia,Not Stated,"Medical Procedure, Surgical",Emergency laparotomy vs. None,"hospitalized, undergoing surgery",Not Stated,Not Stated,"Female, Male",Full,,3.00,Not Stated,12.64,United States,2012,14.25
29487,Surgery and Obstetric Care are Highly Cost-Effective Interventions in a Sub-Saharan African District Hospital: A Three-Month Single-Institution Study of Surgical Costs and Outcomes,"BACKGROUND: The Lancet recently sponsored a commission examining the role of surgery in global health. There is a paucity of published information on the cost-effectiveness of surgery in low- and middle-income countries, a key metric in the prioritisation of limited resources. METHODS: All patients undergoing emergency laparotomy, elective and emergency inguinal hernia repair, elective and emergency caesarean section, amputation, fracture manipulation, or fracture fixation over a 3 months period in a single district African hospital were assessed. World Health Organisation global burden of disease (GBD) methodology was used to calculate the disability-adjusted life years (DALYs) saved for each patient (using global and local life expectancy). Fully loaded costs were calculated for each patient's care and providing the overall surgical service. Cost-effectiveness was calculated in year 2012 US$ per DALY saved for each procedure and overall. RESULTS: A total of 428 patients were included, with an overall cost-effectiveness of $10.70 per DALY averted. The cost-effectiveness of individual procedures (global life expectancy) was: Amputation-$17.66; Emergency caesarean section-$7.42; Elective caesarean section-$20.50; Emergency laparotomy-$8.62; Elective hernia repair-$15.26; Emergency hernia repair-$4.36; Fracture/dislocation reduction-$69.03; Fracture/dislocation fixation-$225.89. CONCLUSIONS: Surgery is a highly cost-effective healthcare measure in the setting of an African district hospital. The presented outcomes demonstrate that surgery is on a par with better-recognised and funded interventions such as HIV anti-retrovirals, malaria prevention and diarrhoea treatment. There are recognised limitations with the GBD methodology used here; however, this remains the best way to investigate the cost-effectiveness of health interventions. This study provides useful information on an, at present, under-studied field.",2016-XX-20973,26470700,World J Surg,Geoffrey Roberts,2016,40 / 1,14-20,No,26470700,"Geoffrey Roberts; Charlotte Roberts; Amy Jamieson; Caris Grimes; Gemma Conn; Robert Bleichrodt; Surgery and Obstetric Care are Highly Cost-Effective Interventions in a Sub-Saharan African District Hospital: A Three-Month Single-Institution Study of Surgical Costs and Outcomes, World J Surg, 2016 Jan; 40(1):0364-2313; 14-20",DALY,Zambia,Not Stated,"Medical Procedure, Surgical",Emergency inguinal hernia repair vs. None,"hospitalized, undergoing surgery",Not Stated,Not Stated,"Female, Male",Full,,3.00,Not Stated,6.66,United States,2012,7.51
29488,Surgery and Obstetric Care are Highly Cost-Effective Interventions in a Sub-Saharan African District Hospital: A Three-Month Single-Institution Study of Surgical Costs and Outcomes,"BACKGROUND: The Lancet recently sponsored a commission examining the role of surgery in global health. There is a paucity of published information on the cost-effectiveness of surgery in low- and middle-income countries, a key metric in the prioritisation of limited resources. METHODS: All patients undergoing emergency laparotomy, elective and emergency inguinal hernia repair, elective and emergency caesarean section, amputation, fracture manipulation, or fracture fixation over a 3 months period in a single district African hospital were assessed. World Health Organisation global burden of disease (GBD) methodology was used to calculate the disability-adjusted life years (DALYs) saved for each patient (using global and local life expectancy). Fully loaded costs were calculated for each patient's care and providing the overall surgical service. Cost-effectiveness was calculated in year 2012 US$ per DALY saved for each procedure and overall. RESULTS: A total of 428 patients were included, with an overall cost-effectiveness of $10.70 per DALY averted. The cost-effectiveness of individual procedures (global life expectancy) was: Amputation-$17.66; Emergency caesarean section-$7.42; Elective caesarean section-$20.50; Emergency laparotomy-$8.62; Elective hernia repair-$15.26; Emergency hernia repair-$4.36; Fracture/dislocation reduction-$69.03; Fracture/dislocation fixation-$225.89. CONCLUSIONS: Surgery is a highly cost-effective healthcare measure in the setting of an African district hospital. The presented outcomes demonstrate that surgery is on a par with better-recognised and funded interventions such as HIV anti-retrovirals, malaria prevention and diarrhoea treatment. There are recognised limitations with the GBD methodology used here; however, this remains the best way to investigate the cost-effectiveness of health interventions. This study provides useful information on an, at present, under-studied field.",2016-XX-20973,26470700,World J Surg,Geoffrey Roberts,2016,40 / 1,14-20,No,26470700,"Geoffrey Roberts; Charlotte Roberts; Amy Jamieson; Caris Grimes; Gemma Conn; Robert Bleichrodt; Surgery and Obstetric Care are Highly Cost-Effective Interventions in a Sub-Saharan African District Hospital: A Three-Month Single-Institution Study of Surgical Costs and Outcomes, World J Surg, 2016 Jan; 40(1):0364-2313; 14-20",DALY,Zambia,Not Stated,"Medical Procedure, Surgical",Elective inguinal hernia repair vs. None,"hospitalized, undergoing surgery",Not Stated,Not Stated,"Female, Male",Full,,3.00,Not Stated,24.03,United States,2012,27.09
29489,Surgery and Obstetric Care are Highly Cost-Effective Interventions in a Sub-Saharan African District Hospital: A Three-Month Single-Institution Study of Surgical Costs and Outcomes,"BACKGROUND: The Lancet recently sponsored a commission examining the role of surgery in global health. There is a paucity of published information on the cost-effectiveness of surgery in low- and middle-income countries, a key metric in the prioritisation of limited resources. METHODS: All patients undergoing emergency laparotomy, elective and emergency inguinal hernia repair, elective and emergency caesarean section, amputation, fracture manipulation, or fracture fixation over a 3 months period in a single district African hospital were assessed. World Health Organisation global burden of disease (GBD) methodology was used to calculate the disability-adjusted life years (DALYs) saved for each patient (using global and local life expectancy). Fully loaded costs were calculated for each patient's care and providing the overall surgical service. Cost-effectiveness was calculated in year 2012 US$ per DALY saved for each procedure and overall. RESULTS: A total of 428 patients were included, with an overall cost-effectiveness of $10.70 per DALY averted. The cost-effectiveness of individual procedures (global life expectancy) was: Amputation-$17.66; Emergency caesarean section-$7.42; Elective caesarean section-$20.50; Emergency laparotomy-$8.62; Elective hernia repair-$15.26; Emergency hernia repair-$4.36; Fracture/dislocation reduction-$69.03; Fracture/dislocation fixation-$225.89. CONCLUSIONS: Surgery is a highly cost-effective healthcare measure in the setting of an African district hospital. The presented outcomes demonstrate that surgery is on a par with better-recognised and funded interventions such as HIV anti-retrovirals, malaria prevention and diarrhoea treatment. There are recognised limitations with the GBD methodology used here; however, this remains the best way to investigate the cost-effectiveness of health interventions. This study provides useful information on an, at present, under-studied field.",2016-XX-20973,26470700,World J Surg,Geoffrey Roberts,2016,40 / 1,14-20,No,26470700,"Geoffrey Roberts; Charlotte Roberts; Amy Jamieson; Caris Grimes; Gemma Conn; Robert Bleichrodt; Surgery and Obstetric Care are Highly Cost-Effective Interventions in a Sub-Saharan African District Hospital: A Three-Month Single-Institution Study of Surgical Costs and Outcomes, World J Surg, 2016 Jan; 40(1):0364-2313; 14-20",DALY,Zambia,Not Stated,"Medical Procedure, Surgical",Fracture/dislocation reduction vs. None,"hospitalized, undergoing surgery",Not Stated,Not Stated,"Female, Male",Full,,3.00,Not Stated,98.73,United States,2012,111.29
29490,Surgery and Obstetric Care are Highly Cost-Effective Interventions in a Sub-Saharan African District Hospital: A Three-Month Single-Institution Study of Surgical Costs and Outcomes,"BACKGROUND: The Lancet recently sponsored a commission examining the role of surgery in global health. There is a paucity of published information on the cost-effectiveness of surgery in low- and middle-income countries, a key metric in the prioritisation of limited resources. METHODS: All patients undergoing emergency laparotomy, elective and emergency inguinal hernia repair, elective and emergency caesarean section, amputation, fracture manipulation, or fracture fixation over a 3 months period in a single district African hospital were assessed. World Health Organisation global burden of disease (GBD) methodology was used to calculate the disability-adjusted life years (DALYs) saved for each patient (using global and local life expectancy). Fully loaded costs were calculated for each patient's care and providing the overall surgical service. Cost-effectiveness was calculated in year 2012 US$ per DALY saved for each procedure and overall. RESULTS: A total of 428 patients were included, with an overall cost-effectiveness of $10.70 per DALY averted. The cost-effectiveness of individual procedures (global life expectancy) was: Amputation-$17.66; Emergency caesarean section-$7.42; Elective caesarean section-$20.50; Emergency laparotomy-$8.62; Elective hernia repair-$15.26; Emergency hernia repair-$4.36; Fracture/dislocation reduction-$69.03; Fracture/dislocation fixation-$225.89. CONCLUSIONS: Surgery is a highly cost-effective healthcare measure in the setting of an African district hospital. The presented outcomes demonstrate that surgery is on a par with better-recognised and funded interventions such as HIV anti-retrovirals, malaria prevention and diarrhoea treatment. There are recognised limitations with the GBD methodology used here; however, this remains the best way to investigate the cost-effectiveness of health interventions. This study provides useful information on an, at present, under-studied field.",2016-XX-20973,26470700,World J Surg,Geoffrey Roberts,2016,40 / 1,14-20,No,26470700,"Geoffrey Roberts; Charlotte Roberts; Amy Jamieson; Caris Grimes; Gemma Conn; Robert Bleichrodt; Surgery and Obstetric Care are Highly Cost-Effective Interventions in a Sub-Saharan African District Hospital: A Three-Month Single-Institution Study of Surgical Costs and Outcomes, World J Surg, 2016 Jan; 40(1):0364-2313; 14-20",DALY,Zambia,Not Stated,"Medical Procedure, Surgical",Fracture/dislocation fixation vs. None,"hospitalized, undergoing surgery",Not Stated,Not Stated,"Female, Male",Full,,3.00,Not Stated,336.78,United States,2012,379.64
29491,Scaling up of HIV treatment for men who have sex with men in Bangkok: a modelling and costing study,"BACKGROUND: Despite the high prevalence of HIV in men who have sex with men (MSM) in Bangkok, little investment in HIV prevention for MSM has been made. HIV testing and treatment coverage remains low. Through a pragmatic programme-planning approach, we assess possible service linkage and provision of HIV testing and antiretroviral treatment (ART) to MSM in Bangkok, and the most cost-effective scale-up strategy. METHODS: We obtained epidemiological and service capacity data from the Thai National Health Security Office database for 2011. We surveyed 13 representative medical facilities for detailed operational costs of HIV-related services for sexually active MSM (defined as having sex with men in the past 12 months) in metropolitan Bangkok. We estimated the costs of various ART scale-up scenarios, accounting for geographical accessibility across Bangkok. We used an HIV transmission population-based model to assess the cost-effectiveness of the scenarios. FINDINGS: For present HIV testing (23% [95% CI 17-36] of MSM at high risk in 2011) and ART provision (20% of treatment-eligible MSM at high risk on ART in 2011) to be sustained, a US$73.8 million ($51.0 million to $97.0 million) investment during the next decade would be needed, which would link an extra 43,000 (27,900-58,000) MSM at high risk to HIV testing and 5100 (3500-6700) to ART, achieving an ART coverage of 44% for MSM at high risk in 2022. An additional $55.3 million investment would link an extra 46,700 (30,300-63,200) MSM to HIV testing and 12,600 (8800-16,600) to ART, achieving universal ART coverage of this population by 2022. This increased investment is achievable within present infrastructure capacity. Consequently, an estimated 5100 (3600-6700) HIV-related deaths and 3700 (2600-4900) new infections could be averted in MSM by 2022, corresponding to a 53% reduction in deaths and a 35% reduction in infections from 2012 levels. The expansion would cost an estimated $10,809 (9071-13,274) for each HIV-related death, $14,783 (12,389-17,960) per new infection averted, and $351 (290-424) per disability-adjusted life-year averted. INTERPRETATION: Spare capacity in Bangkok's medical facilities can be used to expand ART access for MSM with large epidemiological benefits. The expansion needs increased funding directed to MSM services, but given the epidemiological trends, is probably cost effective. Our modelling approach and outcomes are likely to be applicable to other settings. FUNDING: World Bank Group and Australian National Health and Medical Research Council.",2015-99-21065,26423002,Lancet HIV,Lei Zhang,2015,2 / 5,e200-7,No,26423002,"Lei Zhang; Nittaya Phanuphak; Klara Henderson; Siriporn Nonenoy; Sasiwan Srikaew; Andrew J Shattock; Cliff C Kerr; Brenda Omune; Frits van Griensven; Sutayut Osornprasop; Robert Oelrichs; Jintanat Ananworanich; David P Wilson; Scaling up of HIV treatment for men who have sex with men in Bangkok: a modelling and costing study, Lancet HIV, 2015 May; 2(5):2352-3018; e200-7",DALY,Thailand,Not Stated,"Health Education or Behavior, Pharmaceutical, Screening","Scaling up of testing and treatment of HIV with universal antiretroviral treatment (ART), HIV testing services, conventional peer-educator outreach, mobile point-of-care night clinics vs. Standard/Usual Care",men who have sex with men at high risk of HIV,Not Stated,19 Years,Male,Full,", costs data for 10 years",3.00,3.00,418,United States,2012,471.19
29492,Review of a two-year methicillin-resistant Staphylococcus aureus screening program and cost-effectiveness analysis in Singapore,"BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) poses an increasingly large disease and economic burden worldwide. The effectiveness of screening programs in the tropics is poorly understood. The aims of this study are: (i) to analyze the factors affecting MRSA colonization at admission and acquisition during hospitalization and (ii) to evaluate the cost-effectiveness of a screening program which aims to control MRSA incidence during hospitalization. METHODS: We conducted a retrospective case-control study of patients admitted to the Communicable Disease Centre (CDC) in Singapore between Jan 2009 and Dec 2010 when there was an ongoing selective screening and isolation program. Risk factors contributing to MRSA colonization on admission and acquisition during hospital stay were evaluated using a logistic regression model. In addition, a cost-effectiveness analysis was conducted to determine the cost per disability-adjusted life year (DALY) averted due to implementing the screening and isolation program. RESULTS: The average prevalence rate of screened patients at admission and the average acquisition rate at discharge during the study period were 12.1 and 4.8 % respectively. Logistic regression models showed that older age (adjusted odds ratio (OR) 1.03, 95 % CI 1.02-1.04, p < 0.001) and dermatological conditions (adjusted OR 1.49, 95 % CI 1.11-1.20, p = 0.008) were independently associated with an increased risk of MRSA colonization at admission. Age (adjusted OR 1.02, 95 % CI 1.01-1.03, p = 0.002) and length of stay in hospital (adjusted OR 1.04, 95 % CI 1.03-1.06, p < 0.001) were independent factors associated with MRSA acquisition during hospitalization. The screening and isolation program reduced the acquisition rate by 1.6 % and was found to be cost saving. For the whole study period, the program cost US$129,916, while it offset hospitalization costs of US$103,869 and loss of productivity costs of US$50,453 with -400 $/DALY averted. DISCUSSION: This study is the first to our knowledge that evaluates the cost-effectiveness of screening and isolation of MRSA patients in a tropical country. Another unique feature of the analysis is the evaluation of acquisition rates among specific types of patients (dermatological, HIV and infectious disease patients)and the comparison of the cost-effectiveness of screening and isolation between them. CONCLUSIONS: Overall our results indicate high MRSA prevalence that can be cost effectively reduced by selective screening and isolation programs in Singapore.",2015-99-21075,26419926,J Manag Care Spec Pharm,Mar-Kyaw Win,2015,15 /,391,No,26419926,"Mar-Kyaw Win; Tarek Abdellatif Aly Soliman; Linda Kay Lee; Chia Siong Wong; Angela Chow; Brenda Ang; Carrasco L Roman; Yee-Sin Leo; Review of a two-year methicillin-resistant Staphylococcus aureus screening program and cost-effectiveness analysis in Singapore, J Manag Care Spec Pharm, 2015; 15():2376-1032; 391",DALY,Singapore,Not Stated,Screening,Screening program to control methicillin-resistant staphylococcus aureus (MRSA) incidence during hospitalization vs. Standard/Usual Care,Not Stated,Not Stated,12 Years,"Female, Male",Full,", 1 year cost time horizon",Not Stated,3.00,Not Stated,United States,2014,Not Stated
29493,Review of a two-year methicillin-resistant Staphylococcus aureus screening program and cost-effectiveness analysis in Singapore,"BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) poses an increasingly large disease and economic burden worldwide. The effectiveness of screening programs in the tropics is poorly understood. The aims of this study are: (i) to analyze the factors affecting MRSA colonization at admission and acquisition during hospitalization and (ii) to evaluate the cost-effectiveness of a screening program which aims to control MRSA incidence during hospitalization. METHODS: We conducted a retrospective case-control study of patients admitted to the Communicable Disease Centre (CDC) in Singapore between Jan 2009 and Dec 2010 when there was an ongoing selective screening and isolation program. Risk factors contributing to MRSA colonization on admission and acquisition during hospital stay were evaluated using a logistic regression model. In addition, a cost-effectiveness analysis was conducted to determine the cost per disability-adjusted life year (DALY) averted due to implementing the screening and isolation program. RESULTS: The average prevalence rate of screened patients at admission and the average acquisition rate at discharge during the study period were 12.1 and 4.8 % respectively. Logistic regression models showed that older age (adjusted odds ratio (OR) 1.03, 95 % CI 1.02-1.04, p < 0.001) and dermatological conditions (adjusted OR 1.49, 95 % CI 1.11-1.20, p = 0.008) were independently associated with an increased risk of MRSA colonization at admission. Age (adjusted OR 1.02, 95 % CI 1.01-1.03, p = 0.002) and length of stay in hospital (adjusted OR 1.04, 95 % CI 1.03-1.06, p < 0.001) were independent factors associated with MRSA acquisition during hospitalization. The screening and isolation program reduced the acquisition rate by 1.6 % and was found to be cost saving. For the whole study period, the program cost US$129,916, while it offset hospitalization costs of US$103,869 and loss of productivity costs of US$50,453 with -400 $/DALY averted. DISCUSSION: This study is the first to our knowledge that evaluates the cost-effectiveness of screening and isolation of MRSA patients in a tropical country. Another unique feature of the analysis is the evaluation of acquisition rates among specific types of patients (dermatological, HIV and infectious disease patients)and the comparison of the cost-effectiveness of screening and isolation between them. CONCLUSIONS: Overall our results indicate high MRSA prevalence that can be cost effectively reduced by selective screening and isolation programs in Singapore.",2015-99-21075,26419926,J Manag Care Spec Pharm,Mar-Kyaw Win,2015,15 /,391,No,26419926,"Mar-Kyaw Win; Tarek Abdellatif Aly Soliman; Linda Kay Lee; Chia Siong Wong; Angela Chow; Brenda Ang; Carrasco L Roman; Yee-Sin Leo; Review of a two-year methicillin-resistant Staphylococcus aureus screening program and cost-effectiveness analysis in Singapore, J Manag Care Spec Pharm, 2015; 15():2376-1032; 391",DALY,Singapore,Not Stated,Screening,Screening program to control methicillin-resistant staphylococcus aureus (MRSA) incidence during hospitalization vs. Standard/Usual Care,Not Stated,Not Stated,12 Years,"Female, Male",Full,", 1 year cost time horizon",Not Stated,3.00,Not Stated,United States,2014,Not Stated
29494,Review of a two-year methicillin-resistant Staphylococcus aureus screening program and cost-effectiveness analysis in Singapore,"BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) poses an increasingly large disease and economic burden worldwide. The effectiveness of screening programs in the tropics is poorly understood. The aims of this study are: (i) to analyze the factors affecting MRSA colonization at admission and acquisition during hospitalization and (ii) to evaluate the cost-effectiveness of a screening program which aims to control MRSA incidence during hospitalization. METHODS: We conducted a retrospective case-control study of patients admitted to the Communicable Disease Centre (CDC) in Singapore between Jan 2009 and Dec 2010 when there was an ongoing selective screening and isolation program. Risk factors contributing to MRSA colonization on admission and acquisition during hospital stay were evaluated using a logistic regression model. In addition, a cost-effectiveness analysis was conducted to determine the cost per disability-adjusted life year (DALY) averted due to implementing the screening and isolation program. RESULTS: The average prevalence rate of screened patients at admission and the average acquisition rate at discharge during the study period were 12.1 and 4.8 % respectively. Logistic regression models showed that older age (adjusted odds ratio (OR) 1.03, 95 % CI 1.02-1.04, p < 0.001) and dermatological conditions (adjusted OR 1.49, 95 % CI 1.11-1.20, p = 0.008) were independently associated with an increased risk of MRSA colonization at admission. Age (adjusted OR 1.02, 95 % CI 1.01-1.03, p = 0.002) and length of stay in hospital (adjusted OR 1.04, 95 % CI 1.03-1.06, p < 0.001) were independent factors associated with MRSA acquisition during hospitalization. The screening and isolation program reduced the acquisition rate by 1.6 % and was found to be cost saving. For the whole study period, the program cost US$129,916, while it offset hospitalization costs of US$103,869 and loss of productivity costs of US$50,453 with -400 $/DALY averted. DISCUSSION: This study is the first to our knowledge that evaluates the cost-effectiveness of screening and isolation of MRSA patients in a tropical country. Another unique feature of the analysis is the evaluation of acquisition rates among specific types of patients (dermatological, HIV and infectious disease patients)and the comparison of the cost-effectiveness of screening and isolation between them. CONCLUSIONS: Overall our results indicate high MRSA prevalence that can be cost effectively reduced by selective screening and isolation programs in Singapore.",2015-99-21075,26419926,J Manag Care Spec Pharm,Mar-Kyaw Win,2015,15 /,391,No,26419926,"Mar-Kyaw Win; Tarek Abdellatif Aly Soliman; Linda Kay Lee; Chia Siong Wong; Angela Chow; Brenda Ang; Carrasco L Roman; Yee-Sin Leo; Review of a two-year methicillin-resistant Staphylococcus aureus screening program and cost-effectiveness analysis in Singapore, J Manag Care Spec Pharm, 2015; 15():2376-1032; 391",DALY,Singapore,Not Stated,Screening,Screening program to control methicillin-resistant staphylococcus aureus (MRSA) incidence during hospitalization vs. Standard/Usual Care,Not Stated,Not Stated,12 Years,"Female, Male",Full,", 1 year cost time horizon",Not Stated,3.00,3949,United States,2014,4317.23
29495,Review of a two-year methicillin-resistant Staphylococcus aureus screening program and cost-effectiveness analysis in Singapore,"BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) poses an increasingly large disease and economic burden worldwide. The effectiveness of screening programs in the tropics is poorly understood. The aims of this study are: (i) to analyze the factors affecting MRSA colonization at admission and acquisition during hospitalization and (ii) to evaluate the cost-effectiveness of a screening program which aims to control MRSA incidence during hospitalization. METHODS: We conducted a retrospective case-control study of patients admitted to the Communicable Disease Centre (CDC) in Singapore between Jan 2009 and Dec 2010 when there was an ongoing selective screening and isolation program. Risk factors contributing to MRSA colonization on admission and acquisition during hospital stay were evaluated using a logistic regression model. In addition, a cost-effectiveness analysis was conducted to determine the cost per disability-adjusted life year (DALY) averted due to implementing the screening and isolation program. RESULTS: The average prevalence rate of screened patients at admission and the average acquisition rate at discharge during the study period were 12.1 and 4.8 % respectively. Logistic regression models showed that older age (adjusted odds ratio (OR) 1.03, 95 % CI 1.02-1.04, p < 0.001) and dermatological conditions (adjusted OR 1.49, 95 % CI 1.11-1.20, p = 0.008) were independently associated with an increased risk of MRSA colonization at admission. Age (adjusted OR 1.02, 95 % CI 1.01-1.03, p = 0.002) and length of stay in hospital (adjusted OR 1.04, 95 % CI 1.03-1.06, p < 0.001) were independent factors associated with MRSA acquisition during hospitalization. The screening and isolation program reduced the acquisition rate by 1.6 % and was found to be cost saving. For the whole study period, the program cost US$129,916, while it offset hospitalization costs of US$103,869 and loss of productivity costs of US$50,453 with -400 $/DALY averted. DISCUSSION: This study is the first to our knowledge that evaluates the cost-effectiveness of screening and isolation of MRSA patients in a tropical country. Another unique feature of the analysis is the evaluation of acquisition rates among specific types of patients (dermatological, HIV and infectious disease patients)and the comparison of the cost-effectiveness of screening and isolation between them. CONCLUSIONS: Overall our results indicate high MRSA prevalence that can be cost effectively reduced by selective screening and isolation programs in Singapore.",2015-99-21075,26419926,J Manag Care Spec Pharm,Mar-Kyaw Win,2015,15 /,391,No,26419926,"Mar-Kyaw Win; Tarek Abdellatif Aly Soliman; Linda Kay Lee; Chia Siong Wong; Angela Chow; Brenda Ang; Carrasco L Roman; Yee-Sin Leo; Review of a two-year methicillin-resistant Staphylococcus aureus screening program and cost-effectiveness analysis in Singapore, J Manag Care Spec Pharm, 2015; 15():2376-1032; 391",DALY,Singapore,Not Stated,Screening,Screening program to control methicillin-resistant staphylococcus aureus (MRSA) incidence during hospitalization vs. Standard/Usual Care,Not Stated,Not Stated,12 Years,"Female, Male",Full,", 1 year cost time horizon",Not Stated,3.00,Not Stated,United States,2014,Not Stated
29496,Improving Maternal Care through a State-Wide Health Insurance Program: A Cost and Cost-Effectiveness Study in Rural Nigeria,"BACKGROUND: While the Nigerian government has made progress towards the Millennium Development Goals, further investments are needed to achieve the targets of post-2015 Sustainable Development Goals, including Universal Health Coverage. Economic evaluations of innovative interventions can help inform investment decisions in resource-constrained settings. We aim to assess the cost and cost-effectiveness of maternal care provided within the new Kwara State Health Insurance program (KSHI) in rural Nigeria. METHODS AND FINDINGS: We used a decision analytic model to simulate a cohort of pregnant women. The primary outcome is the incremental cost effectiveness ratio (ICER) of the KSHI scenario compared to the current standard of care. Intervention cost from a healthcare provider perspective included service delivery costs and above-service level costs; these were evaluated in a participating hospital and using financial records from the managing organisations, respectively. Standard of care costs from a provider perspective were derived from the literature using an ingredient approach. We generated 95% credibility intervals around the primary outcome through probabilistic sensitivity analysis (PSA) based on a Monte Carlo simulation. We conducted one-way sensitivity analyses across key model parameters and assessed the sensitivity of our results to the performance of the base case separately through a scenario analysis. Finally, we assessed the sustainability and feasibility of this program's scale up within the State's healthcare financing structure through a budget impact analysis. The KSHI scenario results in a health benefit to patients at a higher cost compared to the base case. The mean ICER (US$46.4/disability-adjusted life year averted) is considered very cost-effective compared to a willingness-to-pay threshold of one gross domestic product per capita (Nigeria, US$ 2012, 2,730). Our conclusion was robust to uncertainty in parameters estimates (PSA: median US$49.1, 95% credible interval 21.9-152.3), during one-way sensitivity analyses, and when cost, quality, cost and utilization parameters of the base case scenario were changed. The sustainability of this program's scale up by the State is dependent on further investments in healthcare. CONCLUSIONS: This study provides evidence that the investment made by the KSHI program in rural Nigeria is likely to have been cost-effective; however, further healthcare investments are needed for this program to be successfully expanded within Kwara State. Policy makers should consider supporting financial initiatives to reduce maternal mortality tackling both supply and demand issues in the access to care.",2015-99-21087,26413788,PLoS One,Gabriela B Gomez,2015,10 / 9,e0139048,No,26413788,"Gabriela B Gomez; Nicola Foster; Daniella Brals; Heleen E Nelissen; Oladimeji A Bolarinwa; Marleen E Hendriks; Alexander C Boers; Diederik van Eck; Nicole Rosendaal; Peju Adenusi; Kayode Agbede; Tanimola M Akande; Michael Boele van Hensbroek; Ferdinand W Wit; Catherine A Hankins; Constance Schultsz; Improving Maternal Care through a State-Wide Health Insurance Program: A Cost and Cost-Effectiveness Study in Rural Nigeria, PLoS One , 2015; 10(9):1932-6203; e0139048",DALY,Nigeria,Not Stated,"Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening, Surgical","State-wide health insurance program includes comprehensive health care, increase to antenatal care (ANC), delivery care, essential obstetric care (EOC) to reduce maternal mortality vs. Standard/Usual Care",pregnant,Not Stated,19 Years,Female,Full,,3.00,3.00,46.4,United States,2012,52.3
29497,An ex-ante economic evaluation of the Maternal and Child Health Voucher Scheme as a decision-making tool in Myanmar,"Reducing child and maternal mortality in order to meet the health-related Millennium Development Goals (MDGs) 4 and 5 remains a major challenge in Myanmar. Inadequate care during pregnancy and labour plays an important role in the maternal mortality rate in Myanmar. A Maternal and Child Health (MCH) Voucher Scheme comprising a subsidization for pregnant women to receive four antenatal care (ANC), delivery and postnatal care (PNC) free-of-charge was planned to help women overcome financial barriers in addition to raising awareness of ANC and delivery with skilled birth attendants (SBA), which can reduce the rate of maternal and neonatal death. This study is part of an ex-ante evaluation of a feasibility study of the MCH Voucher Scheme. A cost-utility analysis was conducted using a decision tree model to assess the cost per disability-adjusted life years (DALYs) averted from the MCH Voucher Scheme compared with the current situation. Most input parameters were obtained from Myanmar context. From the base-case analysis, where the financial burden on households was fully subsidized, the MCH Voucher Scheme increased utilization for ANC from 73% up to 93% and for delivery from SBAs from 51% up to and 71%, respectively; hence, it is considered to be very cost-effective with an incremental cost-effectiveness ratio of 381 027 kyats per DALY averted (2010, price year). From the probabilistic sensitivity analysis, the MCH Voucher Scheme had a 52% chance of being a cost-effective option at 1 GDP per capita threshold compared to the current situation. Given that the Voucher Scheme is currently being implemented in one township in Myanmar as a result of this study, ongoing evaluation of the effectiveness and cost-effectiveness of this scheme is warranted.",2016-XX-21090,26412858,Health Policy Plan,Pritaporn Kingkaew,2016,31 / 4,482-92,No,26412858,"Pritaporn Kingkaew; Pitsaphun Werayingyong; San San Aye; Nilar Tin; Alaka Singh; Phone Myint; Yot Teerawattananon; An ex-ante economic evaluation of the Maternal and Child Health Voucher Scheme as a decision-making tool in Myanmar, Health Policy Plan, 2016 May; 31(4):0268-1080; 482-92",DALY,Myanmar,Not Stated,Maternal / Neonatal / Reproductive Care,"Maternal and child health (MCH) voucher scheme comprising of subsidization to receive four antenatal care (ANC), delivery and postnatal care (PNC) free-of-charge to reduce maternal and neonatal complications vs. Standard/Usual Care",pregnant,40 Years,19 Years,Female,Full,,Not Stated,Not Stated,381027,Myanmar,2010,70552.5
29498,Cost-Effectiveness of Rotavirus Vaccination for Under-Five Children in Iran,"BACKGROUND: Rotavirus diarrhea is one of the most important causes of death among under-five children. Anti-rotavirus vaccination of these children may have a reducing effect on the disease. OBJECTIVES: this study is intended to contribute to health policy-makers of the country about the optimal decision and policy development in this area, by performing cost-effectiveness and cost-utility analysis on anti-rotavirus vaccination for under-5 children. PATIENTS AND METHODS: A cost-effectiveness analysis was performed using a decision tree model to analyze rotavirus vaccination, which was compared with no vaccination with Iran's ministry of health perspective in a 5-year time horizon. Epidemiological data were collected from published and unpublished sources. Four different assumptions were considered to the extent of the disease episode. To analyze costs, the costs of implementing the vaccination program were calculated with 98% coverage and the cost of USD 7 per dose. Medical and social costs of the disease were evaluated by sampling patients with rotavirus diarrhea, and sensitivity analysis was also performed for different episode rates and vaccine price per dose. RESULTS: For the most optimistic assumption for the episode of illness (10.2 per year), the cost per DALY averted is 12,760 and 7,404 for RotaTeq and Rotarix vaccines, respectively, while assuming the episode of illness is 300%, they will be equal to 2,395 and 354, respectively, which will be highly cost-effective. Number of life-years gained is equal to 3,533 years. CONCLUSIONS: Assuming that the illness episodes are 100% and 300% for Rotarix and 300% for Rota Teq, the ratio of cost per DALY averted is highly cost-effective, based on the threshold of the world health organization (< 1 GDP per capita = 4526 USD). The implementation of a national rotavirus vaccination program is suggested.",2015-99-17185,26396704,J Pain Symptom Manage,Sareh Shakerian,2015,25 / 4,e2766,No,26396704,"Sareh Shakerian; Maziar Moradi Lakeh; Abdoulreza Esteghamati; Mohsen Zahraei; Mohsen Yaghoubi; Cost-Effectiveness of Rotavirus Vaccination for Under-Five Children in Iran, J Pain Symptom Manage, 2015 Aug; 25(4):1873-6513; e2766",DALY,Iran,Not Stated,Immunization,Rotavirus vaccination (RotaTeq) vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,12760,United States,2010,15144.86
29499,Cost-Effectiveness of Rotavirus Vaccination for Under-Five Children in Iran,"BACKGROUND: Rotavirus diarrhea is one of the most important causes of death among under-five children. Anti-rotavirus vaccination of these children may have a reducing effect on the disease. OBJECTIVES: this study is intended to contribute to health policy-makers of the country about the optimal decision and policy development in this area, by performing cost-effectiveness and cost-utility analysis on anti-rotavirus vaccination for under-5 children. PATIENTS AND METHODS: A cost-effectiveness analysis was performed using a decision tree model to analyze rotavirus vaccination, which was compared with no vaccination with Iran's ministry of health perspective in a 5-year time horizon. Epidemiological data were collected from published and unpublished sources. Four different assumptions were considered to the extent of the disease episode. To analyze costs, the costs of implementing the vaccination program were calculated with 98% coverage and the cost of USD 7 per dose. Medical and social costs of the disease were evaluated by sampling patients with rotavirus diarrhea, and sensitivity analysis was also performed for different episode rates and vaccine price per dose. RESULTS: For the most optimistic assumption for the episode of illness (10.2 per year), the cost per DALY averted is 12,760 and 7,404 for RotaTeq and Rotarix vaccines, respectively, while assuming the episode of illness is 300%, they will be equal to 2,395 and 354, respectively, which will be highly cost-effective. Number of life-years gained is equal to 3,533 years. CONCLUSIONS: Assuming that the illness episodes are 100% and 300% for Rotarix and 300% for Rota Teq, the ratio of cost per DALY averted is highly cost-effective, based on the threshold of the world health organization (< 1 GDP per capita = 4526 USD). The implementation of a national rotavirus vaccination program is suggested.",2015-99-17185,26396704,J Pain Symptom Manage,Sareh Shakerian,2015,25 / 4,e2766,No,26396704,"Sareh Shakerian; Maziar Moradi Lakeh; Abdoulreza Esteghamati; Mohsen Zahraei; Mohsen Yaghoubi; Cost-Effectiveness of Rotavirus Vaccination for Under-Five Children in Iran, J Pain Symptom Manage, 2015 Aug; 25(4):1873-6513; e2766",DALY,Iran,Not Stated,Immunization,Rotavirus vaccination (Rotarix) vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,7404,United States,2010,8787.82
29500,"Comparison of community-wide, integrated mass drug administration strategies for schistosomiasis and soil-transmitted helminthiasis: a cost-effectiveness modelling study","BACKGROUND: More than 1.5 billion people are affected by schistosomiasis or soil-transmitted helminthiasis. WHO's recommendations for mass drug administration (MDA) against these parasitic infections emphasise treatment of school-aged children, using separate treatment guidelines for these two helminthiases groups. We aimed to evaluate the cost-effectiveness of expanding integrated MDA to the entire community in four settings in Cote d'Ivoire. METHODS: We extended previously published, dynamic, age-structured models of helminthiases transmission to simulate costs and disability averted with integrated MDA (of praziquantel and albendazole) for schistosomiasis and soil-transmitted helminthiasis. We calibrated the model to data for prevalence and intensity of species-specific helminth infection from surveys undertaken in four communities in Cote d'Ivoire between March, 1997, and September, 2010. We simulated a 15-year treatment programme with 75% coverage in only school-aged children; school-aged children and preschool-aged children; adults; and the entire community. Treatment costs were estimated at US$0.74 for school-aged children and $1.74 for preschool-aged children and adults. The incremental cost-effectiveness ratio (ICER) was calculated in 2014 US dollars per disability-adjusted life-year (DALY) averted. FINDINGS: Expanded community-wide treatment was highly cost effective compared with treatment of only school-aged children (ICER $167 per DALY averted) and WHO guidelines (ICER $127 per DALY averted), and remained highly cost effective even if treatment costs for preschool-aged children and adults were ten times greater than those for school-aged children. Community-wide treatment remained highly cost effective even when elimination of helminth infections was not achieved. These findings were robust across the four diverse communities in Cote d'Ivoire, only one of which would have received annual MDA for both schistosomiasis and soil-transmitted helminthiasis under the latest WHO guidelines. Treatment every 6 months was also highly cost effective in three out of four communities. INTERPRETATION: Integrated, community-wide MDA programmes for schistosomiasis and soil-transmitted helminthiasis can be highly cost effective, even in communities with low disease burden in any helminth group. These results support an urgent need to re-evaluate current global guidelines for helminthiases control programmes to include community-wide treatment, increased treatment frequency, and consideration for lowered prevalence thresholds for integrated treatment. FUNDING: Stanford University Medical Scholars Programme, Mount Sinai Hospital-University Health Network AMO Innovation Fund.",2015-99-17212,26385302,Environ Health Perspect,Nathan C Lo,2015,3 / 10,e629-38,No,26385302,"Nathan C Lo; Isaac I Bogoch; Brian G Blackburn; Giovanna Raso; Eliezer K N'Goran; Jean T Coulibaly; Soren L Becker; Howard B Abrams; Jurg Utzinger; Jason R Andrews; Comparison of community-wide, integrated mass drug administration strategies for schistosomiasis and soil-transmitted helminthiasis: a cost-effectiveness modelling study, Environ Health Perspect, 2015 Oct; 3(10):1552-9924; e629-38",DALY,Cte d'Ivoire,Not Stated,Pharmaceutical,Annual mass drug administration for protection against schistosomiasis and/or soil-transmitted helminthiasis (praziquantel and albendazole) vs. None,Not Stated,Not Stated,6 Years,"Female, Male",Full,,3.00,3.00,167,United States,2014,182.57
